Original Article
Estrogen plus Progestin and the Risk of Coronary Heart Disease
N Engl J Med 2003; 349:523-534August 7, 2003
- Abstract
Background
Recent randomized clinical trials have suggested that estrogen plus progestin does not confer cardiac protection and may increase the risk of coronary heart disease (CHD). In this report, we provide the final results with regard to estrogen plus progestin and CHD from the Women's Health Initiative (WHI).
Methods
The WHI included a randomized primary-prevention trial of estrogen plus progestin in 16,608 postmenopausal women who were 50 to 79 years of age at base line. Participants were randomly assigned to receive conjugated equine estrogens (0.625 mg per day) plus medroxyprogesterone acetate (2.5 mg per day) or placebo. The primary efficacy outcome of the trial was CHD (nonfatal myocardial infarction or death due to CHD).
Results
After a mean follow-up of 5.2 years (planned duration, 8.5 years), the data and safety monitoring board recommended terminating the estrogen-plus-progestin trial because the overall risks exceeded the benefits. Combined hormone therapy was associated with a hazard ratio for CHD of 1.24 (nominal 95 percent confidence interval, 1.00 to 1.54; 95 percent confidence interval after adjustment for sequential monitoring, 0.97 to 1.60). The elevation in risk was most apparent at one year (hazard ratio, 1.81 [95 percent confidence interval, 1.09 to 3.01]). Although higher base-line levels of low-density lipoprotein cholesterol were associated with an excess risk of CHD among women who received hormone therapy, higher base-line levels of C-reactive protein, other biomarkers, and other clinical characteristics did not significantly modify the treatment-related risk of CHD.
Conclusions
Estrogen plus progestin does not confer cardiac protection and may increase the risk of CHD among generally healthy postmenopausal women, especially during the first year after the initiation of hormone use. This treatment should not be prescribed for the prevention of cardiovascular disease.
Media in This Article
Figure 1
Differences between the Mean Percent Changes from Base Line to Year 1 in Several Intermediate Outcomes in the Estrogen-plus-Progestin Group as Compared with the Placebo Group.Figure 2
Kaplan–Meier Estimates of Cumulative Hazard Rates of CHD.Article Activity
- Article
Our understanding of the effect of postmenopausal hormone therapy on the risk of coronary heart disease (CHD) has recently undergone a major change. Although previous observational studies had suggested that postmenopausal hormone therapy was associated with a reduction of 40 to 50 percent in the risk of CHD,1,2 recent randomized clinical trials have provided no evidence of cardiac protection and even some evidence of harm with postmenopausal hormone therapy.3-8 The primary findings of the Estrogen plus Progestin trial of the Women's Health Initiative (WHI) suggested an overall increase in the risk of CHD (hazard ratio, 1.29) among women randomly assigned to combined hormone therapy as compared with those assigned to placebo.8 The trial was stopped early, after an average of 5.2 years of follow-up, because it was found that the health risks associated with estrogen plus progestin exceeded the benefits.
It has been hypothesized that divergent findings from observational studies and randomized clinical trials may be at least partially attributable to differences in the clinical characteristics of the study populations, including differences in age, years since menopause, and underlying risk of CHD, as well as methodologic limitations of observational studies.9,10 Moreover, certain biomarkers, including base-line levels of lipoproteins, inflammatory markers, and thrombotic factors, may identify women for whom postmenopausal hormone therapy confers a higher or lower risk of coronary events.11-14
In this article, we present the final results of the WHI trial of the relation between the use of estrogen plus progestin and the risk of CHD. We provide an updated analysis of coronary end points reached through the termination of the trial on July 7, 2002 (previous analyses included end points reached through April 2002). We use centrally adjudicated end points for the primary coronary outcome of nonfatal myocardial infarction or death due to CHD (previous analyses were based on local adjudication) to enhance the uniformity of documentation of outcomes. We also provide results for additional coronary end points, including angina, acute coronary syndromes, and congestive heart failure, and provide detailed analyses of subgroups of women defined according to clinical characteristics and biomarker levels to further elucidate the primary findings.
Methods
Study Population, Recruitment, Study Regimens, and Follow-up
Detailed information about the study population, recruitment methods, study regimens, randomization, blinding, follow-up, data and safety monitoring, and quality assurance has been published previously.8,15 Briefly, eligible women were 50 to 79 years of age at the time of initial screening, were postmenopausal, and were likely to be residing in the same geographic area for at least three years.
Postmenopausal women with an intact uterus at screening were eligible for the trial of combined estrogen and progestin; women who had undergone hysterectomy were eligible for the trial of estrogen alone. The protocol and consent forms were approved by the institutional review boards of the participating institutions, and written informed consent was obtained from all participants. The sample analyzed here consists of the 16,608 women with an intact uterus at base line who were enrolled in the double-blind trial comparing estrogen plus progestin with placebo. The study regimen of combined estrogen and progestin was provided in one daily tablet containing 0.625 mg of oral conjugated equine estrogen and 2.5 mg of medroxyprogesterone acetate (Prempro, Wyeth). The control group received matching placebo.
Ascertainment of Outcomes
CHD was defined as acute myocardial infarction necessitating overnight hospitalization, death due to CHD, or silent myocardial infarction identified on serial electrocardiography.16 The diagnosis of acute myocardial infarction was documented by a review of the medical records according to an algorithm that was adapted from standardized criteria,8,17 including cardiac pain, cardiac enzyme and troponin levels, and electrocardiographic readings. Death due to CHD was defined as death consistent with an underlying cause of CHD plus one or more of the following factors: hospitalization for myocardial infarction within 28 days before death, previous angina or myocardial infarction, death due to a procedure related to CHD, or a death certificate consistent with an underlying cause of CHD. Silent myocardial infarction16 was diagnosed through the comparison of base-line and follow-up electrocardiograms at three and six years. Additional coronary end points included coronary revascularization (coronary-artery bypass grafting [CABG] or percutaneous transluminal coronary angioplasty [PTCA]) confirmed by a review of the medical records, angina necessitating hospitalization (hospital admission for chest pain or other symptoms determined to be due to angina), confirmed angina (hospitalization for angina, with myocardial ischemia confirmed by stress testing or obstructive coronary disease [luminal narrowing of >70 percent] confirmed by coronary angiography), acute coronary syndromes (hospitalization for angina, Q-wave infarction, or non–Q-wave infarction), and congestive heart failure (necessitating hospitalization, with a physician's diagnosis of congestive heart failure and pertinent abnormalities on diagnostic testing corroborated by a review of the medical records). Acute myocardial infarctions and deaths due to CHD were confirmed by central physician-adjudicators and other coronary end points by local adjudicators, all of whom were unaware of the treatment-group assignments. The rate of concordance between the local and central reviews was 90 percent for myocardial infarction and 97 percent for death due to atherosclerotic CHD.
Analyses of Biomarkers
Blood was drawn at base line after a fast lasting a minimum of 10 hours. Serum and plasma samples were shipped to a central repository and stored at –70°C.18 In a random sample of 8.6 percent of participants (oversampled for women from minority groups), the lipid profile was obtained and glucose and insulin were measured at base line, year 1, and year 3. The assay methods have been described previously.18
A nested case–control study of biomarkers, treatment-group assignment, and risk of CHD was also conducted. A total of 205 cases of myocardial infarction or death due to CHD occurring between randomization and February 28, 2001, were included. Controls were selected from the hormone-therapy trial and were matched to the cases according to age, date of randomization, presence or absence of CHD at base line, hysterectomy status, and follow-up time. Additional controls selected for cases of stroke or venous thrombosis were also included; the total number of controls was 513. Methods of testing for the inflammatory and thrombotic markers have been described previously.18 Data analysis was performed with the use of logistic regression.
Statistical Analysis
Primary analyses used time-to-event methods based on the intention-to-treat principle. For coronary outcomes, the time to the event was defined as the number of days between randomization and the first diagnosis after randomization. Comparisons with regard to the primary outcome are presented as hazard ratios with 95 percent confidence intervals that were calculated from Cox proportional-hazards analyses,19 stratified according to age, presence or absence of CHD at base line, and randomization status in the low-fat–diet trial (as in the original report8), and adjusted for the presence or absence of previous CABG or PTCA. Because CHD was the primary outcome of the hormone trial and was an important consideration for stopping the trial early8 (the trial was terminated after the 10th semiannual interim analysis), both nominal 95 percent confidence intervals and 95 percent confidence intervals adjusted for sequential monitoring are provided for the primary coronary end point. For other coronary end points, both nominal confidence intervals and confidence intervals adjusted for multiple (seven) trial outcomes are presented. Secondary analyses included women who adhered fully to the study medication.
Cox models for subgroup analyses were stratified according to age and the presence or absence of CHD at base line, and the consistency of treatment effects among subgroups was assessed by formal tests of interaction. Because of the large number of subgroups considered (at least 36), the results should be interpreted with caution, since some significant findings (at least one or two, based on a 0.05 nominal level of statistical significance) could have occurred by chance alone. All reported P values are two-sided.
Results
Base-Line Characteristics
As described in the original report,8 the base-line characteristics were nearly identical in the two treatment groups. The only base-line variable that differed significantly between the groups was a history of coronary revascularization (present in 1.1 percent of the women in the hormone group and 1.5 percent of those in the placebo group, P=0.04), so this variable was included as a covariate in the Cox models. A total of 8506 women were randomly assigned to estrogen plus progestin, and 8102 were assigned to placebo. The mean (±SD) age was 63.3±7.1 years; 16 percent of the women were members of minority groups; and one quarter of the women had previously used postmenopausal hormone therapy. Approximately 2.4 percent of the women reported previous CHD (myocardial infarction, a coronary revascularization procedure, or both) and 4.4 percent reported previous CHD, stroke, or transient cerebral ischemia. Thus, the prevalence of previous cardiovascular disease was low, and women with such a history were analyzed separately in secondary analyses. The base-line levels of cardiovascular risk factors (36 percent of the women had hypertension, 13 percent were being treated for hypercholesterolemia, 4.4 percent were being treated for diabetes, and 10.5 percent were current smokers) were consistent with those in a generally healthy population of postmenopausal women.
Follow-up and Adherence
Vital status was known for 16,067 women who underwent randomization (96.7 percent), including 485 (2.9 percent) who were known to be deceased. Information on outcomes was up to date for 15,582 women (93.8 percent); for the 541 women (3.3 percent) who were lost to follow-up or who stopped providing information on outcomes before the trial ended, we include all available information. The present report updates information on outcomes through July 7, 2002 (after an average of 5.6 years of follow-up [as compared with 5.2 years in the earlier report8] and a maximum of 8.6 years). As previously reported,8 42 percent of women randomly assigned to estrogen plus progestin and 38 percent of women randomly assigned to placebo stopped taking the study drugs during follow-up — rates that compare favorably with community-based adherence to hormone therapy.20 The cumulative “drop-in” rate — the rate of hormone use initiated by the woman's clinician — was 6.2 percent in the estrogen-plus-progestin group and 10.7 percent in the placebo group by year 6.
Intermediate Biomarkers and Risk Factors for CHD
The results of assessments of CHD biomarkers, including fasting blood lipid, glucose, and insulin levels, in an 8.6 percent subsample of women at base line and at year 1 are shown in Figure 1Figure 1
Differences between the Mean Percent Changes from Base Line to Year 1 in Several Intermediate Outcomes in the Estrogen-plus-Progestin Group as Compared with the Placebo Group.. Women randomly assigned to estrogen plus progestin had greater reductions in the total cholesterol, low-density lipoprotein (LDL) cholesterol, glucose, and insulin levels and greater increases in the high-density lipoprotein (HDL) cholesterol and triglyceride levels than women in the placebo group. Systolic blood pressure at year 1 was 1 mm Hg higher among women receiving hormones than among those receiving placebo (remaining 1 to 2 mm Hg higher during follow-up), although diastolic blood pressure did not differ materially between groups. Body weight and waist circumference at follow-up were slightly lower among women in the hormone group than among those in the placebo group, although the ratio of the waist circumference to the hip circumference did not differ appreciably (Figure 1). Results at year 3 (data not shown) were nearly identical to those at year 1.Clinical Coronary Outcomes
Table 1Table 1
Coronary Outcomes among Women Randomly Assigned to Estrogen plus Progestin, as Compared with Those Assigned to Placebo. shows the rates of CHD (nonfatal myocardial infarction, including silent myocardial infarction, and death due to CHD), coronary revascularization, angina, and congestive heart failure. In adjusted analyses, women randomly assigned to estrogen plus progestin had a risk of CHD that was 24 percent higher than that among women randomly assigned to placebo (hazard ratio, 1.24 [nominal 95 percent confidence interval, 1.00 to 1.54; 95 percent confidence interval with adjustment for sequential monitoring, 0.97 to 1.60]). The hazard ratios were 1.28 for nonfatal myocardial infarction and 1.10 for death due to CHD (total cases of CHD, 335, as compared with 286 in the earlier report8). Absolute rates of CHD were 39 cases per 10,000 person-years and 33 cases per 10,000 person-years for hormone therapy and placebo, respectively. No significant differences were observed with regard to coronary revascularization, hospitalization for angina, confirmed angina, acute coronary syndrome, or congestive heart failure.Additional analyses were conducted to examine the sensitivity of these results to the actual use of study medications. Because a substantial proportion of women stopped taking study pills during follow-up, analyses were performed that censored the data on a woman's history of coronary events six months after she stopped taking the pills (or began taking less than 80 percent of them) or six months after she began nonstudy hormone therapy. These analyses produced higher estimates of the excess risk with estrogen plus progestin. For CHD, the adjusted hazard ratio was 1.50 (95 percent confidence interval, 1.14 to 1.97), and for CHD, revascularization, or angina, the hazard ratio was 1.09 (95 percent confidence interval, 0.90 to 1.31). If discontinuation of treatment and initiation of nonstudy hormone therapy occurred independently of the risk of CHD, it would suggest that the intention-to-treat analyses may underestimate the effect. Such “adherence-based” analyses, however, have limitations and should be interpreted with caution.
Temporal Trends
The cumulative hazard rates of CHD (nonfatal myocardial infarction or death due to CHD) in the two treatment groups are provided in Figure 2Figure 2
Kaplan–Meier Estimates of Cumulative Hazard Rates of CHD.. An elevated risk of CHD with estrogen plus progestin appeared to emerge soon after randomization, and the cumulative rates did not begin to converge until year 6.Hazard ratios for CHD for one-year intervals of follow-up are presented in Table 2Table 2
Estrogen plus Progestin and the Risk of CHD, According to Year of Follow-up.. A substantial elevation in the risk of CHD with estrogen plus progestin occurred in year 1 (hazard ratio, 1.81 [95 percent confidence interval, 1.09 to 3.01]), and a smaller and nonsignificant excess risk occurred in years 2 through 5. In year 6 and beyond, the increased rates in the placebo group resulted in an apparent risk reduction. The trend toward a decreasing relative risk over time was statistically significant. For CHD, revascularization, or angina, the hazard ratio was 1.48 (95 percent confidence interval, 1.03 to 2.11) at one year, but no elevation in the risk was apparent in subsequent years.Subgroup Analyses
To determine whether certain subgroups of women were at particularly high or low risk for CHD (nonfatal myocardial infarction or death due to CHD) with estrogen plus progestin, we examined several demographic and clinical characteristics. In addition, base-line levels of several lipid, inflammatory, and thrombotic biomarkers were assessed as potential modulators of risk. Overall, no subgroup of women except those with higher base-line LDL cholesterol levels had evidence of a pattern of hazard ratios for CHD with postmenopausal hormone therapy that was different from the pattern found among all women. Subgroup analyses were planned a priori; the results of analyses of variables whose influence has greater biologic plausibility are shown in Figure 3Figure 3
Estrogen plus Progestin and the Risk of CHD in Various Subgroups. and Figure 4Figure 4
Estrogen plus Progestin and the Risk of CHD According to Levels of Biomarkers at Base Line., and the remainder are summarized in Table 3Table 3
Estrogen plus Progestin and the Risk of CHD in Various Subgroups. or below.Results of evaluations of the roles of age and the time since menopause in modulating the risk of treatment are shown in Figure 3. No significant interaction between age and treatment was observed. For women in whom menopause had begun less than 10 years previously, 10 to 19 years previously, and 20 or more years previously, the hazard ratios for CHD associated with postmenopausal hormone therapy were 0.89, 1.22, and 1.71, respectively, but the interaction was nonsignificant. Moreover, the presence or absence of vasomotor symptoms (hot flashes, night sweats, or both) was not significantly related to the risk of CHD associated with postmenopausal hormone therapy, either among women 50 to 59 years of age (Figure 3) or in the total cohort (hazard ratios, 1.26 and 1.25, respectively). Previous use of hormone therapy did not appreciably or consistently modify risk, regardless of the duration or temporal proximity of this use. Body-mass index (the weight in kilograms divided by the square of the height in meters) and other anthropometric measures (the waist circumference and the waist-to-hip ratio) did not clearly modulate the risk associated with postmenopausal hormone therapy, nor did the use of aspirin (≥80 mg per day) or statin therapy (Figure 3).
The hazard ratios for CHD with estrogen plus progestin did not differ substantially according to ethnic group, level of education, or CHD-risk-factor status (Table 3) or according to the past use or nonuse of oral contraceptives or levels of physical activity (data not shown). Women who were current smokers or who had a history of hypertension or diabetes, a higher number of risk factors for CHD, or preexisting CHD or other cardiovascular disease did not have a significantly greater excess risk of subsequent coronary events with postmenopausal hormone therapy than did women without these risk factors (Table 3).
Women with higher base-line LDL cholesterol levels appeared to have a greater excess risk of CHD with hormone therapy (P for interaction = 0.01, after adjustment for age, year of randomization, previous CHD, and use of statins at base line) (Figure 4), but this finding may have been due to chance, given the large number of comparisons tested. No other subgroup defined according to biomarker levels, including the C-reactive protein level, had a risk of CHD with postmenopausal hormone therapy that differed significantly from the risk among all women (Figure 4).
Discussion
Our findings in predominantly healthy postmenopausal women 50 to 79 years of age document that combined estrogen and progestin does not confer cardiac protection and may slightly increase the risk of coronary events. These findings extend the information that has been published previously8 by including updated and centrally adjudicated primary coronary end points, providing results for additional coronary outcomes, and examining risk in subgroups of women. The apparent slight increase in risk occurred predominantly for myocardial infarction, with no material increase in the risk of coronary revascularization, angina, or congestive heart failure.
Although the trend toward a decreasing risk of CHD over time with estrogen plus progestin was statistically significant, these results must be interpreted with caution. Hazard ratios for CHD were above 1.0 through year 5 among women assigned to postmenopausal hormone therapy, with particularly elevated rates in year 1. Results in subsequent years were limited by smaller numbers and lower rates of adherence to study medication and were confined to women who were still at risk for a first coronary event. Thus, results in later years could be artifactually lowered by an acceleration of events in earlier years among susceptible women assigned to postmenopausal hormone therapy. In addition, an increase in the rates of events in the placebo group contributed to the apparently lower hazard ratio in year 6 and beyond. Moreover, the increased risk of breast cancer with a longer duration of treatment8 and the adverse overall benefit-to-risk profile would outweigh any coronary benefit that might be seen with longer follow-up.
No subgroup of women except those with higher base-line LDL cholesterol levels had evidence of a risk of CHD with estrogen plus progestin that differed significantly from that observed for all women, and the findings related to LDL cholesterol may have been due to chance. Age, time since menopause, body-mass index, presence or absence of vasomotor symptoms at base line, coronary-risk-factor status, and other variables were not significantly related to the risk of CHD with hormone therapy. Base-line levels of C-reactive protein, fibrinogen, and other biomarkers also did not appear to modulate the risk. None of these variables should be used at this time for risk stratification or for the identification of women who may be more or less vulnerable to an adverse coronary outcome when given hormone therapy.
The absence of the provision of cardiac protection by estrogen plus progestin in our study is consistent with recent findings from randomized trials of postmenopausal hormone therapy in women with CHD. In the Heart Estrogen/Progestin Replacement Study (HERS), estrogen plus progestin had no overall effect on the risk of recurrent coronary events after 4.13 and 6.821 years of follow-up, although the finding of an increased risk after the initiation of treatment was similar to findings in our study. In two angiographic trials,4,6 neither estrogen plus progestin nor estrogen alone was associated with inhibition of the progression of coronary atherosclerosis. The Papworth trial,5 which tested transdermal 17β-estradiol with or without norethindrone, and a trial of estradiol valerate (without progestin) in women with a history of myocardial infarction22 also demonstrated no cardioprotection with postmenopausal hormone therapy. Moreover, the Women's Estrogen for Stroke Trial, which tested oral 17β-estradiol (without progestin), found no overall effect of estrogen on the risk of recurrent stroke and an increase in the risk of fatal stroke.23 Thus, although most of these trials tested the hormone regimen we studied (oral conjugated equine estrogen and medroxyprogesterone acetate), the trials testing transdermal or oral 17β-estradiol or estradiol valerate had similar results.
Previous randomized trials have elucidated several favorable and unfavorable effects of exogenous hormone therapy on intermediate biomarkers. Estrogen therapy reduces plasma levels of LDL cholesterol and increases levels of HDL cholesterol, improves endothelial vascular function, and reduces the levels of fibrinogen, Lp(a) lipoprotein, plasminogen-activator inhibitor type 1, and insulin.11,12,24,25 However, estrogen also has adverse physiological effects, including increasing the plasma levels of triglycerides; small, dense LDL particles; C-reactive protein; and thrombotic markers such as factor VII, prothrombin fragment 1+2, and fibrinopeptide A.11,12,26,27 The addition of a progestin attenuates some of the lipid benefits of estrogen, particularly the increase in HDL cholesterol, but does not seem to counter the prothrombotic effects.12,24
Whether or not certain clinical characteristics of the study population or base-line levels of selected biomarkers predict the coronary effects of postmenopausal hormone therapy is an important area of inquiry. Previous trials have identified few factors that modulate risk. In the HERS trial, despite extensive subgroup analyses, results were found to be generally similar regardless of age and coronary-risk-factor status.3,21,28 Hormone therapy appeared to have a less adverse coronary effect on women who were taking statins than on those who were not, but the differences were not significant.21 Although the findings are of interest in view of antiinflammatory and C-reactive-protein–lowering effects of statins,29 the available data do not support the use of such agents to attenuate the risk of CHD associated with postmenopausal hormone therapy unless and until clinical trials demonstrate such a benefit. Finally, the results of HERS suggested a possible reduction in the risk of CHD with hormone therapy among women with elevated base-line Lp(a) lipoprotein levels13; we did not observe clear evidence of cardiac protection by postmenopausal hormone therapy in this subgroup.
Some limitations of our trial deserve consideration. The WHI tested only a single regimen of estrogen plus progestin. Thus, our results do not necessarily apply to other formulations, doses, or routes of administration of these hormones, and the trial could not distinguish the effects of estrogen from those of progestin. However, randomized trials of oral or transdermal estrogen alone, to date, have had results similar to those of the WHI with regard to CHD.4-6,22 Another limitation is the relatively high rate of discontinuation of hormone therapy in the trial, which tends to decrease the observed treatment effects and may lead to an underestimate of adverse cardiovascular effects. Finally, because of the small size of many of the subgroups examined (which limits the statistical power to detect interactions) and the number of comparisons made (approximately 36 tests for interaction), the findings should be interpreted with caution.
In conclusion, our trial documents that estrogen plus progestin does not have a beneficial effect on the risk of CHD among healthy postmenopausal women. Overall, the risks of treatment outweighed the benefits during 5.6 years of treatment. In view of the combined excess risk of CHD, stroke, venous thromboembolism, and breast cancer, which was not offset by the reduced risk of hip fracture and colorectal cancer,8 this treatment is not a viable intervention for primary prevention. Estrogen-plus-progestin therapy should not be initiated or continued for the prevention of cardiovascular disease. These conclusions are consistent with those of recently published guidelines.30-32 The trial did not address the role of estrogen plus progestin for the short-term treatment of menopausal symptoms, which remains the only clear indication for the use of this regimen.10,31 Information provided in this report about subgroups of women are exploratory and provide direction for future inquiry. In the interim, women with indications for treatment, such as menopausal symptoms, need to consider with their clinicians the suggestion of a slight overall increase in the risk of CHD and information on the risks of other outcomes in making decisions about the use of estrogen-plus-progestin therapy.
Supported by the National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services.
Dr. Assaf is an employee of Pfizer and reports holding stock options in the company; Dr. Wong reports having received grant support from Bristol-Myers Squibb and AstraZeneca.
We are indebted to the participants, investigators, and staff of the WHI for their outstanding dedication and commitment; to Mary Pettinger, M.S., and Philomena Quinn for their expert assistance; and to Medical Research Laboratories (Highland Heights, Ky.) and the Laboratory for Clinical Biochemistry Research (University of Vermont, Burlington) for performing the biomarker assays.
Source Information
From the Division of Preventive Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston (J.E.M.); the Department of Medicine, George Washington University, Washington, D.C. (J.H.); the Department of Preventive Medicine, University of Tennessee Health Science Center, Memphis (K.C.J.); the Program Office, National Heart, Lung, and Blood Institute, Bethesda, Md. (J.E.R.); Memorial Hospital, Brown Medical School, Pawtucket, R.I. (A.R.A.); the Preventive Cardiology Program, New Jersey Medical School, Newark (N.L.L.); the Department of Social and Preventive Medicine, University at Buffalo, Buffalo, N.Y. (M.T.); the Department of Preventive Medicine, Rush–Presbyterian–St. Luke's Medical Center, Chicago (H.R.B.); the Department of Epidemiology, University of Washington, Seattle (S.R.H.); the Division of Cardiology, Harbor–UCLA Research and Education Institute, Torrance, Calif. (R.D.); the Woodruff School of Nursing, Emory University, Atlanta (O.L.S.); the Heart Disease Prevention Program, University of California, Irvine (N.D.W.); the Department of Medicine, Wake Forest University, Winston-Salem, N.C. (J.R.C.); Medical Research Laboratories International, Highland Heights, Ky. (E.S.); and the Departments of Medicine and Pathology, University of Vermont, Burlington (M.C.).
Address reprint requests to Dr. Manson at the Divison of Preventive Medicine, Brigham and Women's Hospital, 900 Commonwealth Ave., Boston, MA 02215, or at jmanson@rics.bwh.harvard.edu.
The Women's Health Initiative (WHI) investigators are listed in the Appendix.
Appendix
The following persons are investigators in the Women's Health Initiative: Program Office (National Heart, Lung, and Blood Institute, Bethesda, Md.): B. Alving, J.E. Rossouw, L. Pottern, S. Ludlam, J.A. McGowan. Clinical Coordinating Center (Fred Hutchinson Cancer Research Center, Seattle): R. Prentice, G. Anderson, A. LaCroix, R. Patterson, A. McTiernan, B. Cochrane, J. Hunt, L. Tinker, C. Kooperberg, M. McIntosh, C.Y. Wang, C. Chen, D. Bowen, A. Kristal, J. Stanford, N. Urban, N. Weiss, E. White; (Bowman Gray School of Medicine, Winston-Salem, N.C.): S. Shumaker, P. Rautaharju, R. Prineas, M. Naughton; (Medical Research Laboratories, Highland Heights, Ky.): E. Stein, P. Laskarzewski; (University of California at San Francisco, San Francisco): S. Cummings, M. Nevitt, M. Dockrell; (University of Minnesota, Minneapolis): L. Harnack; (McKesson BioServices, Rockville, Md.): F. Cammarata, S. Lindenfelser; (University of Washington, Seattle): B. Psaty, S. Heckbert.
Clinical Centers (Albert Einstein College of Medicine, Bronx, N.Y.): S. Wassertheil-Smoller, W. Frishman, J. Wylie-Rosett, D. Barad, R. Freeman; (Baylor College of Medicine, Houston): J. Hays, R. Young, J. Anderson, S. Lithgow, P. Bray; (Brigham and Women's Hospital, Harvard Medical School, Boston): J. Manson, J. Buring, J.M. Gaziano, K. Rexrode, C. Chae; (Brown University, Providence, R.I.): A.R. Assaf, R. Carleton (deceased), C. Wheeler, C. Eaton, M. Cyr; (Emory University, Atlanta): L. Phillips, M. Pedersen, O. Strickland, M. Huber, V. Porter; (Fred Hutchinson Cancer Research Center, Seattle): S.A.A. Beresford, V.M. Taylor, N.F. Woods, M. Henderson, M. Kestin; (George Washington University, Washington, D.C.): J. Hsia, N. Gaba, J. Ascensao, S. Laowattana; (Harbor–UCLA Research and Education Institute, Torrance, Calif.): R. Chlebowski, R. Detrano, A. Nelson, J. Heiner, J. Marshall; (Kaiser Permanente Center for Health Research, Portland, Oreg.): C. Ritenbaugh, B. Valanis, P. Elmer, V. Stevens, N. Karanja; (Kaiser Permanente Division of Research, Oakland, Calif.): B. Caan, S. Sidney, G. Bailey, J. Hirata; (Medical College of Wisconsin, Milwaukee): J. Morley Kotchen, V. Barnabei, T.A. Kotchen, M.A.C. Gilligan, J. Neuner; (MedStar Research Institute, Howard University, Washington, D.C.): B.V. Howard, L. Adams-Campbell, M. Passaro, M. Rainford, T. Agurs-Collins; (Northwestern University, Chicago and Evanston, Ill.): L. Van Horn, P. Greenland, J. Khandekar, K. Liu, C. Rosenberg; (Rush–Presbyterian–St. Luke's Medical Center, Chicago): H. Black, L. Powell, E. Mason; (Stanford Center for Research in Disease Prevention, Stanford University, Stanford, Calif.): M.L. Stefanick, M.A. Hlatky, B. Chen, R.S. Stafford, L.C. Giudice; (State University of New York at Stony Brook, Stony Brook): D. Lane, I. Granek, W. Lawson, G. San Roman, C. Messina; (Ohio State University, Columbus): R. Jackson, R. Harris, D. Frid, W.J. Mysiw, M. Blumenfeld; (University of Alabama at Birmingham, Birmingham): C.E. Lewis, A. Oberman, M.N. Fouad, J.M. Shikany, D. Smith West; (University of Arizona, Tucson and Phoenix): T. Bassford, J. Mattox, M. Ko, T. Lohman; (University at Buffalo, Buffalo, N.Y.): M. Trevisan, J. Wactawski-Wende, S. Graham, J. Chang, E. Smit; (University of California at Davis, Sacramento): J. Robbins, S. Yasmeen, K. Lindfors, J. Stern; (University of California at Irvine, Orange): A. Hubbell, G. Frank, N. Wong, N. Greep, B. Monk; (University of California at Los Angeles, Los Angeles): H. Judd, D. Heber, R. Elashoff; (University of California at San Diego, La Jolla and Chula Vista): R.D. Langer, M.H. Criqui, G.T. Talavera, C.F. Garland, R.E. Hanson; (University of Cincinnati, Cincinnati): M. Gass, S. Wernke, N. Watts; (University of Florida, Gainesville and Jacksonville): M. Limacher, M. Perri, A. Kaunitz, R.S. Williams, Y. Brinson; (University of Hawaii, Honolulu): D. Curb, H. Petrovitch, B. Rodriguez, K. Masaki, S. Sharma; (University of Iowa, Iowa City and Davenport): R. Wallace, J. Torner, S. Johnson, L. Snetselaar, B. VanVoorhis; (University of Massachusetts, Fallon Clinic, Worcester): J. Ockene, M. Rosal, I. Ockene, R. Yood, P. Aronson; (University of Medicine and Dentistry of New Jersey, Newark): N. Lasser, N. Hymowitz, V. Lasser, M. Safford, J. Kostis; (University of Miami, Miami): M.J. O'Sullivan, L. Parker, R. Estape, D. Fernandez; (University of Minnesota, Minneapolis): K.L. Margolis, R.H. Grimm, D.B. Hunninghake, J. LaValleur, K.M. Hall; (University of Nevada, Reno): R. Brunner, S. St. Jeor, W. Graettinger, V. Oujevolk; (University of North Carolina, Chapel Hill): G. Heiss, P. Haines, D. Ontjes, C. Sueta, E. Wells; (University of Pittsburgh, Pittsburgh): L. Kuller, A. Caggiula, J. Cauley, S. Berga, N.C. Milas; (University of Tennessee, Memphis): K.C. Johnson, S. Satterfield, R.W. Ke, J. Vile, F. Tylavsky; (University of Texas Health Science Center, San Antonio): R. Brzyski, R. Schenken, J. Trabal, M. Rodriguez-Sifuentes, C. Mouton; (University of Wisconsin, Madison): C. Allen, D. Laube, P. McBride, J. Mares-Perlman, B. Loevinger; (Wake Forest University School of Medicine, Winston-Salem, N.C.): G. Burke, R. Crouse, L. Parsons, M. Vitolins; (Wayne State University School of Medicine, Hutzel Hospital, Detroit): S. Hendrix, M. Simon, G. McNeeley, P. Gordon, P. Makela.
- References
References
1
Grodstein F ,Stampfer M . The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women. Prog Cardiovasc Dis 1995;38:199-210
CrossRef | Web of Science | Medline2
Grady D ,Rubin SM ,Petitti DB , et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016-1037
Web of Science | Medline3
Hulley S ,Grady D ,Bush T , et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women: Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-613
CrossRef | Web of Science | Medline4
Herrington DM ,Reboussin DM ,Brosnihan KB , et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000;343:522-529
Full Text | Web of Science | Medline5
Clarke SC ,Kelleher J ,Lloyd-Jones H ,Slack M ,Schofiel PM . A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: the Papworth HRT atherosclerosis study. BJOG 2002;109:1056-1062
CrossRef | Web of Science | Medline6
Waters DD ,Alderman EL ,Hsia J , et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. JAMA 2002;288:2432-2440
CrossRef | Web of Science | Medline7
Hemminki E ,McPherson K . Impact of postmenopausal hormone therapy on cardiovascular events and cancer: pooled data from clinical trials. BMJ 1997;315:149-153
CrossRef | Web of Science | Medline8
Writing Group for the Women's Health Initiative Investigators
CrossRef | Web of Science | Medline9
Risks of postmenopausal hormone replacement. JAMA 2002;288:2819-2825
CrossRef | Web of Science10
Grodstein F ,Clarkson TB ,Manson JE . Understanding the divergent data on postmenopausal hormone therapy. N Engl J Med 2003;348:645-650
Full Text | Web of Science | Medline11
Manson JE ,Martin KA . Postmenopausal hormone-replacement therapy. N Engl J Med 2001;345:34-40
Full Text | Web of Science | Medline12
Chae CU, Manson JE. Postmenopausal hormone replacement therapy. In: Hennekens CH, ed. Clinical trials in cardiovascular disease: a companion to Braunwald's Heart Disease. Philadelphia: W.B. Saunders, 1999:399-414.
13
Shlipak MG ,Simon JA ,Vittinghoff E , et al. Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA 2000;283:1845-1852
CrossRef | Web of Science | Medline14
Psaty BM ,Smith NL ,Lemaitre RN , et al. Hormone replacement therapy, prothrombotic mutations, and the risk of incident nonfatal myocardial infarction in postmenopausal women. JAMA 2001;285:906-913
CrossRef | Web of Science | Medline15
Design of the Women's Health Initiative clinical trial and observational study: the Women's Health Initiative Study Group. Control Clin Trials 1998;19:61-109
CrossRef | Medline16
Rautaharju PM ,Park LP ,Chaitman BR ,Rautaharju F ,Zhang ZM . The Novacode criteria for classification of ECG abnormalities and their clinically significant progression and regression. J Electrocardiol 1998;31:157-187
CrossRef | Web of Science | Medline17
Ives DG ,Fitzpatrick AL ,Bild DE , et al. Surveillance and ascertainment of cardiovascular events: the Cardiovascular Health Study. Ann Epidemiol 1995;5:278-285
CrossRef | Medline18
Wassertheil-Smoller S ,Hendrix S ,Limacher M , et al. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative. JAMA 2003;289:2673-2684
CrossRef | Web of Science | Medline19
Cox DR . Regression models and life-tables. J R Stat Soc [B] 1972;34:187-22020
Pilon D ,Castilloux AM ,Lelorier J . Estrogen replacement therapy: determinants of persistence with treatment. Obstet Gynecol 2001;97:97-100
CrossRef | Web of Science | Medline21
Grady D ,Herrington D ,Bittner V , et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002;288:49-57[Erratum, JAMA 2002;288:1064.]
CrossRef | Web of Science | Medline22
Cherry N ,Gilmour K ,Hannaford P , et al. Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. Lancet 2002;360:2001-2008
CrossRef | Web of Science | Medline23
Viscoli CM ,Brass LM ,Kernan WN ,Sarrel PM ,Suissa S ,Horwitz RI . A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 2001;345:1243-1249
Full Text | Web of Science | Medline24
Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995;273:199-208[Erratum, JAMA 1995;274:1676.]
CrossRef | Web of Science25
Mendelsohn ME ,Karas RH . The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999;340:1801-1811
Full Text | Web of Science | Medline26
Cushman M ,Meilahn EN ,Psaty BM ,Kuller LH ,Dobs AS ,Tracy RP . Hormone replacement therapy, inflammation, and hemostasis in elderly women. Arterioscler Thromb Vasc Biol 1999;19:893-899
CrossRef | Web of Science | Medline27
Cushman M ,Legault C ,Barrett-Connor E , et al. Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation 1999;100:717-722
Web of Science | Medline28
Furberg CD ,Vittinghoff E ,Davidson M , et al. Subgroup interactions in the Heart and Estrogen/Progestin Replacement Study: lessons learned. Circulation 2002;105:917-922
CrossRef | Web of Science | Medline29
Albert MA ,Danielson E ,Rifai N ,Rid-ker PM . Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001;286:64-70
CrossRef | Web of Science | Medline30
Mosca L ,Collins P ,Herrington DM , et al. Hormone replacement therapy and cardiovascular disease: a statement for healthcare professionals from the American Heart Assocation. Circulation 2001;104:499-503
CrossRef | Web of Science | Medline31
The North American Menopause Society (NAMS). Report from the NAMS Advisory Panel on Postmenopausal Hormone Therapy. Cleveland: North American Menopause Society, October 3, 2002.
32
U.S. Preventive Services Task Force. Postmenopausal hormone replacement therapy for primary prevention of chronic conditions: recommendations and rationale. Ann Intern Med 2002;137:834-839
Web of Science | Medline
- Citing Articles (558)
Citing Articles
1
Geer Mohammad Ishaq, Pz Tasaduq Hussain, Mir Javid Iqbal, Mohsin Bin Mushtaq. (2013) Risk-Benefit Analysis of Combination Versus Unopposed HRT in Post-Menopausal Women. International Journal of User-Driven Healthcare 1:4, 61-76
CrossRef2
Masakazu Terauchi, Hideo Honjo, Hideki Mizunuma, Takeshi Aso. (2012) Effects of oral estradiol and levonorgestrel on cardiovascular risk markers in postmenopausal women. Archives of Gynecology and Obstetrics
CrossRef3
Kei Izumiyama, Tomohiro Osanai, Shigeki Sagara, Yuko Yamamoto, Taihei Itoh, Takanori Sukekawa, Fumie Nishizaki, Koji Magota, Ken Okumura. (2012) Estrogen attenuates coupling factor 6-induced salt-sensitive hypertension and cardiac systolic dysfunction in mice. Hypertension Research
CrossRef4
Flávia Troncon Rosa, M. Ángeles Zulet, Julio Sérgio Marchini, J. Alfredo Martínez. (2012) Bioactive compounds with effects on inflammation markers in humans. International Journal of Food Sciences and Nutrition120117033311006
CrossRef5
G. Danaei, M. Tavakkoli, M. A. Hernan. (2012) Bias in Observational Studies of Prevalent Users: Lessons for Comparative Effectiveness Research From a Meta-Analysis of Statins. American Journal of Epidemiology
CrossRef6
Gregory T. Wurz, Michael W. DeGregorio. 2011. Evolution of Selective Estrogen and Androgen Receptor Modulators: Status of Current Therapy and New Drug Development. .
CrossRef7
Niels Engberding, Nanette K Wenger. (2011) Management of hypertension in women. Hypertension Research
CrossRef8
(2011) Guía de la ESC/EAS sobre el manejo de las dislipemias. Revista Española de Cardiología 64:12, 1168.e1-1168.e60
CrossRef9
I. Lambrinoudaki, A. Augoulea, E. Armeni, D. Rizos, A. Alexandrou, M. Creatsa, M. Kazani, G. Georgiopoulos, A. Livada, A. Exarchakou, K. Stamatelopoulos. (2011) Menopausal symptoms are associated with subclinical atherosclerosis in healthy recently postmenopausal women. Climacteric1-8
CrossRef10
Chong Shou, Justin Li, Zitao Liu. (2011) Complementary and alternative medicine in the treatment of menopausal symptoms. Chinese Journal of Integrative Medicine 17:12, 883-888
CrossRef11
Peter Vestergaard. (2011) Acute Myocardial Infarction and Atherosclerosis of the Coronary Arteries in Patients Treated with Drugs Against Osteoporosis: Calcium in the Vessels and not the Bones?. Calcified Tissue International
CrossRef12
Cristiano Fava, Marco Ricci, Olle Melander, Pietro Minuz. (2011) Hypertension, Cardiovascular Risk And Polymorphisms In Genes Controlling The Cytochrome P450 Pathway Of Arachidonic Acid: A Sex-Specific Relation?. Prostaglandins & Other Lipid Mediators
CrossRef13
Yee Brendon J., Liu Peter Y., Phillips Craig, Grunstein Ronald R.. 2011. Neuroendocrine aspects of sleep apnea. , 286-299.
CrossRef14
Michael P. Goodman. (2011) Are All Estrogens Created Equal? A Review of Oral vs. Transdermal Therapy. Journal of Women's Health111019074632004
CrossRef15
X.-D. Fu, S. Garibaldi, S. Gopal, K. Polak, G. Palla, S. Spina, P. Mannella, A. R. Genazzani, A. D. Genazzani, T. Simoncini. (2011) Dydrogesterone exerts endothelial anti-inflammatory actions decreasing expression of leukocyte adhesion molecules. Molecular Human Reproduction
CrossRef16
David F. Archer. (2011) Delivery of therapeutic agents to the target tissue. Menopause 18:10, 1040-1041
CrossRef17
Adarsh J. Sai, J. Christopher Gallagher, Xiang Fang. (2011) Effect of hormone therapy and calcitriol on serum lipid profile in postmenopausal older women. Menopause 18:10, 1101-1112
CrossRef18
Nanette J. Tomicek, Timothy S. Lancaster, Donna H. Korzick. (2011) Increased Estrogen Receptor β in Adipose Tissue Is Associated With Increased Intracellular and Reduced Circulating Adiponectin Protein Levels in Aged Female Rats. Gender Medicine 8:5, 325-333
CrossRef19
Woraluk Somboonporn, Sunida Panna, Teerayut Temtanakitpaisan, Srinaree Kaewrudee, Sukree Soontrapa. (2011) Effects of the levonorgestrel-releasing intrauterine system plus estrogen therapy in perimenopausal and postmenopausal women. Menopause 18:10, 1060-1066
CrossRef20
MS Hunter, A Gentry-Maharaj, A Ryan, M Burnell, A Lanceley, L Fraser, I Jacobs, U Menon. (2011) Prevalence, frequency and problem rating of hot flushes persist in older postmenopausal women: impact of age, body mass index, hysterectomy, hormone therapy use, lifestyle and mood in a cross-sectional cohort study of 10 418 British women aged 54-65. BJOG: An International Journal of Obstetrics & Gynaecologyno-no
CrossRef21
Claire L. Curl, James R. Bell, Lea M.D. Delbridge. (2011) ‘Gain’-ful insight into the cardiomyocyte Ca2+ seX factor. Journal of Molecular and Cellular Cardiology
CrossRef22
Lu Gan, Wei Jiang, Yun-Fei Xiao, Lin Deng, Lun-Da Gu, Zhi-Yun Guo, Zhi-Chao Zhou, Dan Wu, Hong-Bo Xin. (2011) Disruption of CD38 gene enhances cardiac functions by elevating serum testosterone in the male null mice. Life Sciences 89:13-14, 491-497
CrossRef23
Eiran Z. Gorodeski. (2011) Atherosclerosis, hormone therapy, and outcomes in younger postmenopausal women. Menopause 18:9, 935-936
CrossRef24
Maryam Darabi, Mohammed Rabbani, Mohsen Ani, Elahe Zarean, Mojtaba Panjehpour, Ahmad Movahedian. (2011) Increased leukocyte ABCA1 gene expression in post-menopausal women on hormone replacement therapy. Gynecological Endocrinology 27:9, 701-705
CrossRef25
Janet S. Carpenter, Margaret M. Byrne, Jamie L. Studts. (2011) Factors related to menopausal symptom management decisions. Maturitas 70:1, 10-15
CrossRef26
Elias Fares, Randi J. Parks, Jennifer K. MacDonald, Jeanne M.S. Egar, Susan E. Howlett. (2011) Ovariectomy enhances SR Ca2+ release and increases Ca2+ spark amplitudes in isolated ventricular myocytes. Journal of Molecular and Cellular Cardiology
CrossRef27
Y. Miyabara, J. Camp, D. Holmes, B. Lahr, K. Bailey, V. M. Miller, A. E. Kearns. (2011) Coronary arterial calcification and thoracic spine mineral density in early menopause. Climacteric 14:4, 438-444
CrossRef28
Sarah Chua, Hui-Liang Wang, Yu-Chun Lin, Chia-Hsien Wu, Tzu-Hsien Tsai, Li-Teh Chang, Ying-Hsien Kao, Chia-Hung Yen, Hon-Kan Yip, Cheuk-Kwan Sun. (2011) Enhanced Expression of Plasminogen Activator Inhibitor May Prevent Cardiac Rupture in Female and Castrated Mice After Myocardial Infarction. Gender Medicine 8:4, 239-251
CrossRef29
Ilaria Spoletini, Cristiana Vitale, Giuseppe MC Rosano. (2011) Biomarkers for predicting postmenopausal coronary heart disease. Biomarkers in Medicine 5:4, 485-495
CrossRef30
K. Sathishkumar, Rebekah Elkins, Uma Yallampalli, Chandra Yallampalli. (2011) Protein restriction during pregnancy induces hypertension in adult female rat offspring – influence of oestradiol. British Journal of Nutrition1-9
CrossRef31
, , Z. Reiner, A. L. Catapano, G. De Backer, I. Graham, M.-R. Taskinen, O. Wiklund, S. Agewall, E. Alegria, M. J. Chapman, P. Durrington, S. Erdine, J. Halcox, R. Hobbs, J. Kjekshus, P. P. Filardi, G. Riccardi, R. F. Storey, D. Wood, , J. Bax, A. Vahanian, A. Auricchio, H. Baumgartner, C. Ceconi, V. Dean, C. Deaton, R. Fagard, G. Filippatos, C. Funck-Brentano, D. Hasdai, R. Hobbs, A. Hoes, P. Kearney, J. Knuuti, P. Kolh, T. McDonagh, C. Moulin, D. Poldermans, B. A. Popescu, Z. Reiner, U. Sechtem, P. A. Sirnes, M. Tendera, A. Torbicki, P. Vardas, P. Widimsky, S. Windecker, D. Reviewers:, C. Funck-Brentano, D. Poldermans, G. Berkenboom, J. De Graaf, O. Descamps, N. Gotcheva, K. Griffith, G. F. Guida, S. Gulec, Y. Henkin, K. Huber, Y. A. Kesaniemi, J. Lekakis, A. J. Manolis, P. Marques-Vidal, L. Masana, J. McMurray, M. Mendes, Z. Pagava, T. Pedersen, E. Prescott, Q. Rato, G. Rosano, S. Sans, A. Stalenhoef, L. Tokgozoglu, M. Viigimaa, M. E. Wittekoek, J. L. Zamorano. (2011) ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). European Heart Journal 32:14, 1769-1818
CrossRef32
Alberico L. Catapano, Željko Reiner, Guy De Backer, Ian Graham, Marja-Riitta Taskinen, Olov Wiklund, Stefan Agewall, Eduardo Alegria, M. John Chapman, Paul Durrington, Serap Erdine, Julian Halcox, Richard Hobbs, John Kjekshus, Pasquale Perrone Filardi, Gabriele Riccardi, Robert F. Storey, David Wood. (2011) ESC/EAS Guidelines for the management of dyslipidaemias. Atherosclerosis 217:1, 3-46
CrossRef33
Bei Jiang, Chunhui Ma, Timothy Motley, Fredi Kronenberg, Edward J. Kennelly. (2011) Phytochemical fingerprinting to thwart black cohosh adulteration: a 15 Actaea species analysis. Phytochemical Analysis 22:4, 339-351
CrossRef34
Holly L. Thacker. (2011) Assessing Risks and Benefits of Nonhormonal Treatments for Vasomotor Symptoms in Perimenopausal and Postmenopausal Women. Journal of Women's Health 20:7, 1007-1016
CrossRef35
Melinda B Davis, Claire S Duvernoy. (2011) How to stay heart healthy in 2011: considerations for the primary prevention of cardiovascular disease in women. Women's Health 7:4, 433-451
CrossRef36
Alberico L. Catapano, Željko Reiner, Guy De Backer, Ian Graham, Marja-Riitta Taskinen, Olov Wiklund, Stefan Agewall, Eduardo Alegria, M. John Chapman, Paul Durrington, Serap Erdine, Julian Halcox, Richard Hobbs, John Kjekshus, Pasquale Perrone Filardi, Gabriele Riccardi, Robert F. Storey, David Wood. (2011) ESC/EAS Guidelines for the management of dyslipidaemias. Atherosclerosis 217, 1-44
CrossRef37
Donna Shoupe. (2011) Individualizing hormone therapy to minimize risk: accurate assessment of risks and benefits. Women's Health 7:4, 475-485
CrossRef38
Mark D. Huffman, Mohammed K. Ali, K. M. Venkat Narayan. (2011) Should There Be a Different Cardiovascular Prevention Polypill Strategy for Women and Men?. Current Cardiovascular Risk Reports 5:3, 280-286
CrossRef39
Cyrus Chargari, Krassen M. Kirov, Marc A. Bollet, Nicolas Magné, Lionel Védrine, Serge Cremades, Philippe Beuzeboc, Alain Fourquet, Youlia M. Kirova. (2011) Cardiac toxicity in breast cancer patients: From a fractional point of view to a global assessment. Cancer Treatment Reviews 37:4, 321-330
CrossRef40
A. H. E. M. Maas, Y. T. van der Schouw, V. Regitz-Zagrosek, E. Swahn, Y. E. Appelman, G. Pasterkamp, H. ten Cate, P. M. Nilsson, M. V. Huisman, H. C. G. Stam, K. Eizema, M. Stramba-Badiale. (2011) Red alert for women's heart: the urgent need for more research and knowledge on cardiovascular disease in women: Proceedings of the Workshop held in Brussels on Gender Differences in Cardiovascular disease, 29 September 2010. European Heart Journal 32:11, 1362-1368
CrossRef41
Krystina G. Sorwell, Steven G. Kohama, Henryk F. Urbanski. (2011) Perimenopausal regulation of steroidogenesis in the nonhuman primate. Neurobiology of Aging
CrossRef42
Angela Boldo, William B. White. (2011) Blood Pressure Effects of the Oral Contraceptive and Postmenopausal Hormone Therapies. Endocrinology & Metabolism Clinics of North America 40:2, 419-432
CrossRef43
Z. Sanad, H. Ellakwa, B. Desouky. (2011) Comparison of alendronate and raloxifene in postmenopausal women with osteoporosis. Climacteric 14:3, 369-377
CrossRef44
Pauliina Tuomikoski, Olavi Ylikorkala, Tomi S. Mikkola. (2011) Menopausal hot flushes and vascular health. Annals of Medicine 43:4, 283-291
CrossRef45
Judith L. Meadows, Douglas E. Vaughan. (2011) Endothelial biology in the post-menopausal obese woman. Maturitas 69:2, 120-125
CrossRef46
B Freidlin, E L Korn. (2011) Assessing causal relationships between treatments and clinical outcomes: always read the fine print. Bone Marrow Transplantation
CrossRef47
Jean C. McSweeney, Christina M. Pettey, Elaine Souder, Sarah Rhoads. (2011) Disparities in Women's Cardiovascular Health. Journal of Obstetric, Gynecologic, & Neonatal Nursing 40:3, 362-371
CrossRef48
Cynthia Arslanian-Engoren. (2011) Women's Risk Factors and Screening for Coronary Heart Disease. Journal of Obstetric, Gynecologic, & Neonatal Nursing 40:3, 337-347
CrossRef49
Janet S. Carpenter, Jamie L. Studts, Margaret M. Byrne. (2011) A systematic review of menopausal symptom management decision aid trials. Maturitas 69:1, 11-21
CrossRef50
Nanette J. Tomicek, Jennifer L. Miller-Lee, J. Craig Hunter, Donna H. Korzick. (2011) Estrogen Receptor Beta Does Not Influence Ischemic Tolerance in the Aged Female Rat Heart. Cardiovascular Therapeuticsno-no
CrossRef51
R. Scott Wright, Jeffrey L. Anderson, Cynthia D. Adams, Charles R. Bridges, Donald E. Casey, Steven M. Ettinger, Francis M. Fesmire, Theodore G. Ganiats, Hani Jneid, A. Michael Lincoff, Eric D. Peterson, George J. Philippides, Pierre Theroux, Nanette K. Wenger, James Patrick Zidar. (2011) 2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction. Journal of the American College of Cardiology 57:19, e215-e367
CrossRef52
Amina A. Chaudhry, Gail Berkenblit, Allen L. Gifford, Joseph Cofrancesco, James Sosman, Lynn E. Sullivan. (2011) Update in HIV Medicine for the Generalist. Journal of General Internal Medicine 26:5, 538-542
CrossRef53
Sarah H Lindsey, Kyle A Carver, Eric R Prossnitz, Mark C Chappell. (2011) Vasodilation in Response to the GPR30 Agonist G-1 is Not Different From Estradiol in the mRen2.Lewis Female Rat. Journal of Cardiovascular Pharmacology 57:5, 598-603
CrossRef54
J. Studd. (2011) ‘PROFOX’ – the post HRT nightmare. Climacteric 14:2, 217-219
CrossRef55
S. Yang, R. L. Prentice. (2011) Estimation of the 2-sample hazard ratio function using a semiparametric model. Biostatistics 12:2, 354-368
CrossRef56
Matthew A. Allison, JoAnn E. Manson. (2011) Age, hormone therapy use, coronary heart disease, and mortality. Menopause 18:3, 243-245
CrossRef57
Daniel O. Stram, Yuan Liu, Katherine D. Henderson, Jane Sullivan-Halley, Jianning Luo, Tanmai Saxena, Peggy Reynolds, Ellen T. Chang, Susan L. Neuhausen, Pamela L. Horn-Ross, Leslie Bernstein, Giske Ursin. (2011) Age-specific effects of hormone therapy use on overall mortality and ischemic heart disease mortality among women in the California Teachers Study. Menopause 18:3, 253-261
CrossRef58
P. E. Lonning. (2011) The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuum. Annals of Oncology 22:3, 503-514
CrossRef59
Sam Hanash. (2011) Progress in Mining the Human Proteome for Disease Applications. OMICS: A Journal of Integrative Biology 15:3, 133-139
CrossRef60
Xiao-Ping Yang, Jane F Reckelhoff. (2011) Estrogen, hormonal replacement therapy and cardiovascular disease. Current Opinion in Nephrology and Hypertension 20:2, 133-138
CrossRef61
S. Mitchell Harman, Eric Vittinghoff, Eliot A. Brinton, Matthew J. Budoff, Marcelle I. Cedars, Rogerio A. Lobo, George R. Merriam, Virginia M. Miller, Frederick Naftolin, Lubna Pal, Nanette Santoro, Hugh S. Taylor, Dennis M. Black. (2011) Timing and Duration of Menopausal Hormone Treatment May Affect Cardiovascular Outcomes. The American Journal of Medicine 124:3, 199-205
CrossRef62
E. Puerta, J. Oberto, M. Guerra, E. Reyna, J. Mejia, N. Reyna, D. Torres, J. Santos. (2011) Efectos del estradiol-drospirenona o estradiol-trimegestona sobre los lípidos y lipoproteínas en menopáusicas. Clínica e Investigación en Ginecología y Obstetricia 38:2, 50-55
CrossRef63
Jennifer M Grossman. (2011) Osteoporosis prevention. Current Opinion in Rheumatology 23:2, 203-210
CrossRef64
Alfred O. Mueck, Xiangyan Ruan. (2011) Benefits and risks during HRT: main safety issue breast cancer. Hormone Molecular Biology and Clinical Investigation 5:2, 105-116
CrossRef65
Howard N. Hodis, Wendy J. Mack. (2011) A “window of opportunity:” The reduction of coronary heart disease and total mortality with menopausal therapies is age- and time-dependent. Brain Research 1379, 244-252
CrossRef66
Miller, Franklin G., Joffe, Steven, . (2011) Equipoise and the Dilemma of Randomized Clinical Trials. New England Journal of Medicine 364:5, 476-480
Full Text67
N. Botto, S. Maffei, S. Manfredi, M. G. Colombo, A. M. Mazzone, M G. Andreassi. (2011) Prothrombotic mutations, family history and the risk of thrombosis in postmenopausal women: implications for hormone replacement therapy. Climacteric 14:1, 25-30
CrossRef68
K. L. Rand, J. L. Otte, D. Flockhart, D. Hayes, A. M. Storniolo, V. Stearns, N. L. Henry, A. Nguyen, S. Lemler, J. Hayden, S. Jeter, J. S. Carpenter. (2011) Modeling hot flushes and quality of life in breast cancer survivors. Climacteric 14:1, 171-180
CrossRef69
Luigi Gennari, Daniela Merlotti, Konstantinos Stolakis, Ranuccio Nuti. (2011) Lasofoxifene, from the preclinical drug discovery to the treatment of postmenopausal osteoporosis. Expert Opinion on Drug Discovery 6:2, 205-217
CrossRef70
Bruno Fabris, Riccardo Candido, Monica Bortoletto, Barbara Toffoli, Stella Bernardi, Marco Stebel, Moreno Bardelli, Lorena Zentilin, Mauro Giacca, Renzo Carretta. (2011) Stimulation of cardiac apoptosis in ovariectomized hypertensive rats: potential role of the renin–angiotensin system. Journal of Hypertension 29:2, 273-281
CrossRef71
S. L. Mumford, E. F. Schisterman, A. M. Siega-Riz, A. J. Gaskins, J. Wactawski-Wende, T. J. VanderWeele. (2011) Effect of Dietary Fiber Intake on Lipoprotein Cholesterol Levels Independent of Estradiol in Healthy Premenopausal Women. American Journal of Epidemiology 173:2, 145-156
CrossRef72
Karin Schenck-Gustafsson, Mark Brincat, C. Tamer Erel, Marco Gambacciani, Irene Lambrinoudaki, Mette H. Moen, Florence Tremollieres, Svetlana Vujovic Serge Rozenberg, Margaret Rees. (2011) EMAS position statement: Managing the menopause in the context of coronary heart disease. Maturitas 68:1, 94-97
CrossRef73
David M Goldberg. (2011) Science at the Crossroads: Fact or Fiction?. Journal of Medical Biochemistry 30:2, 79-92
CrossRef74
J. Christopher Gallagher, Jeffrey P. Levine. (2011) Preventing osteoporosis in symptomatic postmenopausal women. Menopause 18:1, 109-118
CrossRef75
Myoungseok Han. (2011) Metabolic Syndrome Emerging from Menopause. The Journal of Korean Society of Menopause 17:3, 127
CrossRef76
M. A. Martinez-Gonzalez, D. Corella, J. Salas-Salvado, E. Ros, M. I. Covas, M. Fiol, J. Warnberg, F. Aros, V. Ruiz-Gutierrez, R. M. Lamuela-Raventos, J. Lapetra, M. A. Munoz, J. A. Martinez, G. Saez, L. Serra-Majem, X. Pinto, M. T. Mitjavila, J. A. Tur, M. d. P. Portillo, R. Estruch, . (2010) Cohort Profile: design and methods of the PREDIMED study. International Journal of Epidemiology
CrossRef77
Kevin Hawkins, Rajeshwari Mittapally, Joanne Chang, Gerard G. Nahum, Joseph Gricar. (2010) Burden of illness of hypertension among women using menopausal hormone therapy: a US perspective. Current Medical Research and Opinion 26:12, 2823-2832
CrossRef78
Rebecca Hardy. (2010) Vasomotor menopausal symptoms and risk of coronary heart disease. Menopause1
CrossRef79
Layla Al-Nakkash, Brandon Markus, Lyn Batia, Walter C. Prozialeck, Tom L. Broderick. (2010) Genistein Induces Estrogen-Like Effects in Ovariectomized Rats but Fails to Increase Cardiac GLUT4 and Oxidative Stress. Journal of Medicinal Food 13:6, 1369-1375
CrossRef80
Gong-Jhe Wu, Jie-Jen Lee, Duen-Suey Chou, Thanasekaran Jayakumar, George Hsiao, Wei-Fan Chen, Joen-Rong Sheu. (2010) Inhibitory signaling of 17β-estradiol in platelet activation: The pivotal role of cyclic AMP-mediated nitric oxide synthase activation. European Journal of Pharmacology 649:1-3, 140-149
CrossRef81
R. L. Santos, E. B. Marin, W. L. S. Gonçalves, N. S. Bissoli, G. R. Abreu, M. R. Moysés. (2010) Sex differences in the coronary vasodilation induced by 17 β-oestradiol in the isolated perfused heart from spontaneously hypertensive rats. Acta Physiologica 200:3, 203-210
CrossRef82
Myra S. Hunter, Eleanor Mann. (2010) A cognitive model of menopausal hot flushes and night sweats. Journal of Psychosomatic Research 69:5, 491-501
CrossRef83
Jane F. Reckelhoff, Christine Maric. (2010) Sex and gender differences in cardiovascular–renal physiology and pathophysiology. Steroids 75:11, 745-746
CrossRef84
John C. Stevenson, Gemma Durand, Elke Kahler, Tomasz Pertyński. (2010) Oral ultra-low dose continuous combined hormone replacement therapy with 0.5mg 17β-oestradiol and 2.5mg dydrogesterone for the treatment of vasomotor symptoms: Results from a double-blind, controlled study. Maturitas 67:3, 227-232
CrossRef85
O. Ortmann, C. Lattrich, K. Diedrich. (2010) Hormontherapie (HT) in der Peri- und Postmenopause. Der Gynäkologe 43:10, 839-847
CrossRef86
Jared W. Magnani, Eiran Z. Gorodeski. (2010) Cardiovascular epidemiology of postinfarction angina and menopause age. Menopause 17:5, 896-897
CrossRef87
Seung Do Choi, Emma M. Steinberg, Hae Hyeog Lee, Frederick Naftolin. (2010) The "Timing Hypothesis" remains a valid explanation of differential cardioprotective effects of menopausal hormone treatment. Menopause1
CrossRef88
Qurat-ul-ain Jelani, Stuart D. Katz. (2010) Treatment of Anemia in Heart Failure. Cardiology in Review 18:5, 240-250
CrossRef89
Salvatore Mottillo, Kristian B. Filion, Jacques Genest, Lawrence Joseph, Louise Pilote, Paul Poirier, Stéphane Rinfret, Ernesto L. Schiffrin, Mark J. Eisenberg. (2010) The Metabolic Syndrome and Cardiovascular Risk. Journal of the American College of Cardiology 56:14, 1113-1132
CrossRef90
2010. Bibliography. , 321-339.
CrossRef91
C. J. Haines, E. Farrell. (2010) Menopause management: a cardiovascular risk-based approach. Climacteric 13:4, 328-339
CrossRef92
Rogerio A. Lobo, Tom B. Clarkson. (2010) Different mechanisms for benefit and risk of coronary heart disease and stroke in early postmenopausal women. Menopause1
CrossRef93
(2010) Climacteric commentaries. Climacteric 13:4, 395-402
CrossRef94
R. D. Langer. (2010) On the need to clarify and disseminate contemporary knowledge of hormone therapy initiated near menopause. Climacteric 13:4, 303-306
CrossRef95
E. Boschitsch, S. Mayerhofer, D. Magometschnigg. (2010) Hypertension in women: the role of progesterone and aldosterone. Climacteric 13:4, 307-313
CrossRef96
M.L. Stefanick. (2010) Postmenopausal hormone therapy and cardiovascular disease in women. Nutrition, Metabolism and Cardiovascular Diseases 20:6, 451-458
CrossRef97
David F. Archer. (2010) Tissue-Selective Estrogen Complexes. Drugs & Aging 27:7, 533-544
CrossRef98
Ikbal Kaygusuz, Nilgun Ozturk Turhan, Candan Iltemir Duvan, Cemile Koca, Murat Aydin. (2010) Effect of genistein therapy on plasma levels of asymmetric dimethylarginine in healthy postmenopausal women: a randomized, placebo-controlled study. Fertility and Sterility 94:2, 764-766
CrossRef99
Michael E. Mendelsohn, Richard H. Karas. (2010) Rapid progress for non-nuclear estrogen receptor signaling. Journal of Clinical Investigation 120:7, 2277-2279
CrossRef100
Pauliina Tuomikoski, Petri Haapalahti, Seppo Sarna, Olavi Ylikorkala, Tomi S. Mikkola. (2010) Vasomotor hot flushes and 24-hour ambulatory blood pressure in normotensive women: A placebo-controlled trial on post-menopausal hormone therapy. Annals of Medicine 42:5, 334-343
CrossRef101
R. S. Boxer, A. Kleppinger, J. Brindisi, R. Feinn, J. A. Burleson, A. M. Kenny. (2010) Effects of dehydroepiandrosterone (DHEA) on cardiovascular risk factors in older women with frailty characteristics. Age and Ageing 39:4, 451-458
CrossRef102
Y. Zhang. (2010) Cardiovascular diseases in American women. Nutrition, Metabolism and Cardiovascular Diseases 20:6, 386-393
CrossRef103
Muhammad Bayu Sasongko, Tien Yin Wong, Jie Jin Wang. (2010) Retinal microvascular structure: determinants and potential utility of novel imaging measurements. Expert Review of Ophthalmology 5:3, 353-363
CrossRef104
(2010) Reevaluating Erythropoiesis-Stimulating Agents. New England Journal of Medicine 362:18, 1742-1744
Full Text105
Shirin Kalyan, Christine L Hitchcock, Sandra Sirrs, Morris Pudek, Jerilynn C Prior. (2010) Cardiovascular and Metabolic Effects of Medroxyprogesterone Acetate versus Conjugated Equine Estrogen After Premenopausal Hysterectomy with Bilateral Ovariectomy. Pharmacotherapy 30:5, 442-452
CrossRef106
Megan Krause, Thomas L. Wheeler, Holly E. Richter, Thomas E. Snyder. (2010) Systemic Effects of Vaginally Administered Estrogen Therapy. Female Pelvic Medicine & Reconstructive Surgery 16:3, 188-195
CrossRef107
James K. Pru. (2010) Exercise restores autonomic balance in menopause and after cardiovascular events. Menopause1
CrossRef108
Hyeon Chang Kim, Philip Greenland, Jacques E. Rossouw, JoAnn E. Manson, Barbara B. Cochrane, Norman L. Lasser, Marian C. Limacher, Donald M. Lloyd-Jones, Karen L. Margolis, Jennifer G. Robinson. (2010) Multimarker Prediction of Coronary Heart Disease Risk. Journal of the American College of Cardiology 55:19, 2080-2091
CrossRef109
Pauliina Tuomikoski, Petri Haapalahti, Olavi Ylikorkala, Tomi S. Mikkola. (2010) Vasomotor hot flushes and 24-hour ambulatory blood pressure in recently post-menopausal women. Annals of Medicine 42:3, 216-222
CrossRef110
Andrea Cignarella, Mario Kratz, Chiara Bolego. (2010) Emerging role of estrogen in the control of cardiometabolic disease. Trends in Pharmacological Sciences 31:4, 183-189
CrossRef111
E. Windler, A.O. Mueck, B.C. Zyriax, O. Ortmann. (2010) Herz-Kreislauf-Risiko und Hormontherapie in der Postmenopause. Der Gynäkologe 43:4, 301-307
CrossRef112
Christos J Markopoulos, Alexandra K Tsaroucha, Helen J Gogas. (2010) Effect of aromatase inhibitors on the lipid profile of postmenopausal breast cancer patients. Clinical Lipidology 5:2, 245-254
CrossRef113
D. Noss, D. Klemperer, C. Wetzel, O. Ortmann. (2010) Risikokommunikation. Der Gynäkologe 43:4, 276-281
CrossRef114
Ruth Clapauch, Anete S. Mecenas, Priscila A. Maranhão, Eliete Bouskela. (2010) Endothelial-mediated microcirculatory responses to an acute estradiol test are influenced by time since menopause, cumulative hormone exposure, and vasomotor symptoms. Menopause1
CrossRef115
Manuel Naves-Díaz, Natalia Carrillo-López, Aránzazu Rodríguez-Rodríguez, Socorro Braga, Teresa Fernández-Coto, Jose Miguel Lopez-Novoa, Francisco López-Hernández, Jorge B. Cannata-Andía. (2010) Differential effects of 17β-estradiol and raloxifene on bone and lipid metabolism in rats with chronic kidney disease and estrogen insufficiency. Menopause1
CrossRef116
P. Hadji. (2010) Stellenwert der Hormontherapie (HT) zum Erhalt der Knochengesundheit postmenopausaler Frauen. Der Gynäkologe 43:4, 294-300
CrossRef117
Joan Tan Garcia, Florante Gonzaga, Delfin Tan, Toon Yaa Ng, Pau Ling Oei, Cathryn W.B. Chan. (2010) Use of a multibotanical (Nutrafem) for the relief of menopausal vasomotor symptoms. Menopause 17:2, 303-308
CrossRef118
Eliot A. Brinton. (2010) Hot flashes and hormone use. Menopause 17:2, 223-225
CrossRef119
Chien-Chang Chen, Chih-Chan Lin, Tsung-Ming Lee. (2010) 17β-estradiol decreases vulnerability to ventricular arrhythmias by preserving Connexin43 protein in infarcted rats. European Journal of Pharmacology 629:1-3, 73-81
CrossRef120
Kun Hyung Kim, Kyung Won Kang, Dong Il Kim, Hyung Jun Kim, Hyun Min Yoon, Jin Moo Lee, Jae Cheol Jeong, Myeong Soo Lee, Hee Jung Jung, Sun-Mi Choi. (2010) Effects of acupuncture on hot flashes in perimenopausal and postmenopausal women-a multicenter randomized clinical trial. Menopause 17:2, 269-280
CrossRef121
JoAnn V. Pinkerton, Christine J. Guico-Pabia, Hugh S. Taylor. (2010) Menstrual cycle-related exacerbation of disease. American Journal of Obstetrics and Gynecology 202:3, 221-231
CrossRef122
Giuseppe Mercuro, Martino Deidda, Alessandra Piras, Christian Cadeddu Dessalvi, Silvia Maffei, Giuseppe MC Rosano. (2010) Gender determinants of cardiovascular risk factors and diseases. Journal of Cardiovascular Medicine 11:3, 207-220
CrossRef123
Yen Y. Tan, Gerrie-Cor M. Gast, Yvonne T. van der Schouw. (2010) Gender differences in risk factors for coronary heart disease. Maturitas 65:2, 149-160
CrossRef124
Z-m Liu, S C Ho, Y-m Chen, Y P Ho. (2010) A mild favorable effect of soy protein with isoflavones on body composition—a 6-month double-blind randomized placebo-controlled trial among Chinese postmenopausal women. International Journal of Obesity 34:2, 309-318
CrossRef125
Nina Carroll. (2010) A Review of Transdermal Nonpatch Estrogen Therapy for the Management of Menopausal Symptoms. Journal of Women's Health 19:1, 47-55
CrossRef126
&NA;. (2010) Management of osteoporosis in postmenopausal women. Menopause 17:1, 25-54
CrossRef127
Weng-Foung Huang, Yi-Wen Tsai, Yu-Wen Wen, Fei-Yuan Hsiao, Ken N. Kuo, Chia-Rung Tsai. (2010) Osteoporosis treatment and atrial fibrillation. Menopause 17:1, 57-63
CrossRef128
Hyung-Jun Kim, Kang-Hyun Leem, Myoung-Hee Kim. (2010) Correlation between Subjective and Objective Measurement of Climacteric Women's Hot Flashes. Journal of Korean Academy of Nursing 40:6, 765
CrossRef129
Miguel A. Hernán. (2010) The Hazards of Hazard Ratios. Epidemiology 21:1, 13-15
CrossRef130
Pauliina Tuomikoski, Tomi S. Mikkola, Esa Hämäläinen, Matti J. Tikkanen, Ursula Turpeinen, Olavi Ylikorkala. (2010) Biochemical markers for cardiovascular disease in recently postmenopausal women with or without hot flashes. Menopause 17:1, 145-151
CrossRef131
Shari S. Bassuk, JoAnn E. Manson. 2010. Gender-Specific Aspects of Selected Coronary Heart Disease Risk FactorsA Summary of the Epidemiologic Evidence. , 162-174.
CrossRef132
Wolfgang Junge, Volker El-Samalouti, Christoph Gerlinger, Matthias Schaefers. (2009) Effects of menopausal hormone therapy on hemostatic parameters, blood pressure, and body weight: Open-label comparison of randomized treatment with estradiol plus drospirenone versus estradiol plus norethisterone acetate. European Journal of Obstetrics & Gynecology and Reproductive Biology 147:2, 195-200
CrossRef133
Alfred O. Mueck, Harald Seeger, Kai-J. Bühling. (2009) Use of dydrogesterone in hormone replacement therapy. Maturitas 65, S51-S60
CrossRef134
John C. Stevenson, Howard N. Hodis, James H. Pickar, Rogerio A. Lobo. (2009) Coronary heart disease and menopause management: The swinging pendulum of HRT. Atherosclerosis 207:2, 336-340
CrossRef135
Till Freudenberger, Marc Oppermann, Andrea Marzoll, Hans-Karl Heim, Peter Mayer, Georg Kojda, Artur A. Weber, Karsten Schrör, Jens W. Fischer. (2009) Differential effects of medroxyprogesterone acetate on thrombosis and atherosclerosis in mice. British Journal of Pharmacology 158:8, 1951-1960
CrossRef136
Luigi Gennari, Daniela Merlotti, Ranuccio Nuti. (2009) Lasofoxifene: a new-generation SERM for the treatment of postmenopausal osteoporosis. Expert Review of Obstetrics & Gynecology 4:6, 607-617
CrossRef137
Stacie E. Geller, Lee P. Shulman, Richard B. van Breemen, Suzanne Banuvar, Ying Zhou, Geena Epstein, Samad Hedayat, Dejan Nikolic, Elizabeth C. Krause, Colleen E. Piersen, Judy L. Bolton, Guido F. Pauli, Norman R. Farnsworth. (2009) Safety and efficacy of black cohosh and red clover for the management of vasomotor symptoms. Menopause 16:6, 1156-1166
CrossRef138
Whitney Wharton, Maritza Dowling, Christine M. Khosropour, Cynthia Carlsson, Sanjay Asthana, Carey E. Gleason. (2009) Cognitive benefits of hormone therapy: Cardiovascular factors and healthy-user bias. Maturitas 64:3, 182-187
CrossRef139
N. Gavrilova, S. T. Lindau. (2009) Salivary Sex Hormone Measurement in a National, Population-Based Study of Older Adults. The Journals of Gerontology Series B: Psychological Sciences and Social Sciences 64B:Supplement 1, i94-i105
CrossRef140
Marcello Maggio, Gian Paolo Ceda, Fulvio Lauretani, Stefania Bandinelli, Carmelinda Ruggiero, Jack M. Guralnik, E. Jeffrey Metter, Shari M. Ling, Giuseppe Paolisso, Giorgio Valenti, Anne R. Cappola, Luigi Ferrucci. (2009) Relationship Between Higher Estradiol Levels and 9-Year Mortality in Older Women: The Invecchiare in Chianti Study. Journal of the American Geriatrics Society 57:10, 1810-1815
CrossRef141
Pauliina Tuomikoski, Pia Ebert, Per-Henrik Groop, Petri Haapalahti, Hanna Hautamäki, Mats Rönnback, Olavi Ylikorkala, Tomi S. Mikkola. (2009) Effect of Hot Flushes on Vascular Function. Obstetrics & Gynecology 114:4, 777-785
CrossRef142
Wulf Palinski, Eric Nicolaides, Antonio Liguori, Claudio Napoli. (2009) Influence of Maternal Dysmetabolic Conditions During Pregnancy on Cardiovascular Disease. Journal of Cardiovascular Translational Research 2:3, 277-285
CrossRef143
Sung Kee Ryu, Ehtisham Mahmud, Sotirios Tsimikas. (2009) Estrogen-Eluting Stents. Journal of Cardiovascular Translational Research 2:3, 240-244
CrossRef144
V. M. Miller, D. M. Black, E. A. Brinton, M. J. Budoff, M. I. Cedars, H. N. Hodis, R. A. Lobo, J. E. Manson, G. R. Merriam, F. Naftolin, N. Santoro, H. S. Taylor, S. M. Harman. (2009) Using Basic Science to Design a Clinical Trial: Baseline Characteristics of Women Enrolled in the Kronos Early Estrogen Prevention Study (KEEPS). Journal of Cardiovascular Translational Research 2:3, 228-239
CrossRef145
Francesco Perticone, Angela Sciacqua, Raffaele Maio, Maria Perticone, Irma Laino, Rosamaria Bruni, Serena Di Cello, Giulia Galiano Leone, Laura Greco, Francesco Andreozzi, Giorgio Sesti. (2009) Renal function predicts cardiovascular outcomes in southern Italian postmenopausal women. European Journal of Cardiovascular Prevention & Rehabilitation 16:4, 481-486
CrossRef146
David D Dore, Amal N Trivedi, Vincent Mor, Kate L Lapane. (2009) Association Between Extent of Thiazolidinedione Exposure and Risk of Acute Myocardial Infarction. Pharmacotherapy 29:7, 775-783
CrossRef147
Pantelis Panopalis, Jinoos Yazdany. (2009) Bone health in systemic lupus erythematosus. Current Rheumatology Reports 11:3, 177-184
CrossRef148
Konstantinos Tziomalos, Vasilios G Athyros, Anthony S Wierzbicki, Dimitri P Mikhailidis. (2009) Lipoprotein a: where are we now?. Current Opinion in Cardiology 24:4, 351-357
CrossRef149
R. L. Prentice, J. E. Manson, R. D. Langer, G. L. Anderson, M. Pettinger, R. D. Jackson, K. C. Johnson, L. H. Kuller, D. S. Lane, J. Wactawski-Wende, R. Brzyski, M. Allison, J. Ockene, G. Sarto, J. E. Rossouw. (2009) Benefits and Risks of Postmenopausal Hormone Therapy When It Is Initiated Soon After Menopause. American Journal of Epidemiology 170:1, 12-23
CrossRef150
E. Banks, K. Canfell. (2009) Invited Commentary: Hormone Therapy Risks and Benefits--The Women's Health Initiative Findings and the Postmenopausal Estrogen Timing Hypothesis. American Journal of Epidemiology 170:1, 24-28
CrossRef151
Carrie W Nemerovski, Michael P Dorsch, Robert U Simpson, Henry G Bone, Keith D Aaronson, Barry E Bleske. (2009) Vitamin D and Cardiovascular Disease. Pharmacotherapy 29:6, 691-708
CrossRef152
N. Agrinier, M. Cournot, J. Ferrières. (2009) Dyslipidémies de la femme après 50ans : le rôle de l’âge et de la ménopause. Annales de Cardiologie et d'Angéiologie 58:3, 159-164
CrossRef153
Mohammadali Boroumand, Mahboubeh Ghaedi, Narges Mohammadtaghvaei, Leila Pourgholi, Maryam Sotoudeh Anvari, Gholamreza Davoodi, Alireza Amirzadegan, Soheil Saadat, Mahmood Sheikhfathollahi, Hamidreza Goodarzynejad. (2009) Lipid profile and inflammatory markers associated with estrogen receptor α PvuII and XbaI gene polymorphisms. Translational Research 153:6, 288-295
CrossRef154
Guy W. Ll Lloyd. (2009) Preventive cardiology and cardiac rehabilitation programmes in women. Maturitas 63:1, 28-33
CrossRef155
Michelle P. Warren. (2009) Menopausal hot flashes. Menopause 16:3, 427
CrossRef156
Matthias Schaefers, Christoph Muysers, Peter Alexandersen, Claus Christiansen. (2009) Effect of microdose transdermal 17β-estradiol compared with raloxifene in the prevention of bone loss in healthy postmenopausal women. Menopause 16:3, 559-565
CrossRef157
Cindy Farquhar, Jane Marjoribanks, Anne Lethaby, Jane A Suckling, Quirine Lamberts, Cindy Farquhar. 2009. Long term hormone therapy for perimenopausal and postmenopausal women. .
CrossRef158
Jennifer M. Croswell, Barnett S. Kramer. (2009) Clinical trial design and evidence-based outcomes in the study of liver diseases. Journal of Hepatology 50:4, 817-826
CrossRef159
T.D. Filippatos, E.N. Liberopoulos, N. Pavlidis, M.S. Elisaf, D.P. Mikhailidis. (2009) Effects of hormonal treatment on lipids in patients with cancer. Cancer Treatment Reviews 35:2, 175-184
CrossRef160
Karin B. Michels, Walter C. Willett. (2009) The Women’s Health Initiative Randomized Controlled Dietary Modification Trial: a post-mortem. Breast Cancer Research and Treatment 114:1, 1-6
CrossRef161
Robert Flaumenhaft, Margaret Nachtigall, Joanna Lowenstein, Lisa Nachtigall, Richard Nachtigall, Lila Nachtigall. (2009) Association of oral but not transdermal estrogen therapy with enhanced platelet reactivity in a subset of postmenopausal women. Menopause 16:2, 407-412
CrossRef162
Chlebowski, Rowan T., Kuller, Lewis H., Prentice, Ross L., Stefanick, Marcia L., Manson, JoAnn E., Gass, Margery, Aragaki, Aaron K., Ockene, Judith K., Lane, Dorothy S., Sarto, Gloria E., Rajkovic, Aleksandar, Schenken, Robert, Hendrix, Susan L., Ravdin, Peter M., Rohan, Thomas E., Yasmeen, Shagufta, Anderson, Garnet, . (2009) Breast Cancer after Use of Estrogen plus Progestin in Postmenopausal Women. New England Journal of Medicine 360:6, 573-587
Full Text163
Robert A. Vogel, Michael Miller. (2009) Cholesterol Goals: Moving from Numbers to Treatment. Clinical Cardiology 32:2, 106-108
CrossRef164
Rochelle Buffenstein, Mario Pinto. (2009) Endocrine function in naturally long-living small mammals. Molecular and Cellular Endocrinology 299:1, 101-111
CrossRef165
Alyde T. de Kraker, Peter Kenemans, Raimond G.V. Smolders, Maurice V.A.M. Kroeks, Marius J. van der Mooren. (2009) Short-term effects of two continuous combined oestrogen–progestogen therapies on several cardiovascular risk markers in healthy postmenopausal women: A randomised controlled trial. European Journal of Obstetrics & Gynecology and Reproductive Biology 142:2, 139-144
CrossRef166
Mary Ann Lumsden, Margaret Rees. (2009) Preface and Introduction. Best Practice & Research Clinical Obstetrics & Gynaecology 23:1, 1-6
CrossRef167
John C. Stevenson. (2009) HRT and cardiovascular disease. Best Practice & Research Clinical Obstetrics & Gynaecology 23:1, 109-120
CrossRef168
G. Fanciulli, A. Delitala, G. Delitala. (2009) Growth hormone, menopause and ageing: no definite evidence for 'rejuvenation' with growth hormone. Human Reproduction Update 15:3, 341-358
CrossRef169
R. D. Langer. (2009) RE: "ESTROGEN PLUS PROGESTIN THERAPY AND BREAST CANCER IN RECENTLY POSTMENOPAUSAL WOMEN". American Journal of Epidemiology 169:6, 784-785
CrossRef170
Masayoshi Hashimoto, Yoshitomo Miyamoto, Chikao Iwai, Yasuaki Matsuda, Eiji Hiraoka, Kenji Kanazawa, Kunihiro Nishimura, Daisuke Sugiyama, Kazuo Ito, Yukio Yamori, Hozuka Akita. (2009) Delivery May Affect Arterial Elasticity in Women. Circulation Journal 73:4, 750-754
CrossRef171
Shelley R. Salpeter, Nicholas S. Buckley, Hau Liu, Edwin E. Salpeter. (2009) The Cost-effectiveness of Hormone Therapy in Younger and Older Postmenopausal Women. The American Journal of Medicine 122:1, 42-52.e2
CrossRef172
Paul P. Connell, Pearse A. Keane, Evelyn C. O'Neill, Rasha W. Altaie, Edward Loane, Kumari Neelam, John M. Nolan, Stephen Beatty. (2009) Risk Factors for Age-Related Maculopathy. Journal of Ophthalmology 2009, 1-39
CrossRef173
Cong Sun, Jie Jin Wang, David A. Mackey, Tien Y. Wong. (2009) Retinal Vascular Caliber: Systemic, Environmental, and Genetic Associations. Survey of Ophthalmology 54:1, 74-95
CrossRef174
Cynthia A. Stuenkel. (2009) Getting to the heart of the matter. Menopause 16:1, 8-10
CrossRef175
Chrisandra L. Shufelt, C. Noel Bairey Merz. (2009) Contraceptive Hormone Use and Cardiovascular Disease. Journal of the American College of Cardiology 53:3, 221-231
CrossRef176
In Cheol Hwang, Myoung Jin Kuk, Kyoung Kon Kim, Ki Bum Lee, Seo Young Na, Kyoung Sik Lee, Heuy Sun Suh. (2009) One Case of Malignant Mixed Müllerian Tumor Developed in a Postmenopausal Woman under Hormone Therapy. Korean Journal of Family Medicine 30:9, 723
CrossRef177
Ellen W. Seely, Steven Grinspoon. 2009. Patient-Oriented ResearchClinical Pathophysiology and Clinical Therapeutics. , 3-12.
CrossRef178
Palmira Pramparo, Herman Schargrodsky, Carlos Boissonnet, Beatriz Marcet Champagne, Honorio Silva, Monica Acevedo, Elinor Wilson. (2008) Cardiovascular risk factors for heart disease and stroke in women by age and time since menopause, in seven Latin American cities: The CARMELA study. CVD Prevention and Control 3:4, 181-189
CrossRef179
Joseph Yeboah, Karen Klein, Bridget Brosnihan, David Reboussin, David M. Herrington. (2008) Effects of hormone therapy on soluble cell adhesion molecules in postmenopausal women with coronary artery disease. Menopause 15:6, 1060-1064
CrossRef180
A. Trifiletti, A. Gaudio, A. Lasco, M. Atteritano, R. Scamardi, M.A. Pizzoleo, N. Morabito, N. Frisina. (2008) Haemostatic effects of phytoestrogen genistein in postmenopausal women. Thrombosis Research 123:2, 231-235
CrossRef181
Dhananjay Vaidya. (2008) Sex hormones and circulating lipoprotein levels. Future Lipidology 3:6, 603-606
CrossRef182
Rogerio A. Lobo. (2008) Inflammation, coronary artery disease, and hormones. Menopause 15:6, 1036-1038
CrossRef183
(2008) Estrogen and progestogen therapy in postmenopausal women. Fertility and Sterility 90:5, S88-S102
CrossRef184
Ross L. Prentice. (2008) Data Analysis Methods and the Reliability of Analytic Epidemiologic Research. Epidemiology 19:6, 785-788
CrossRef185
Miguel A. Herná, James M. Robins. (2008) Authorsʼ Response, Part I: Observational Studies Analyzed Like Randomized Experiments. Epidemiology 19:6, 789-792
CrossRef186
C. Banz, K. Schaudig, A. Schwenkhagen, K. Diedrich. (2008) Kardiovaskuläres Risiko in der Postmenopause und Hormonersatztherapie. Der Gynäkologe 41:11, 879-883
CrossRef187
A. Schwenkhagen, K. Schaudig, C. Banz, K. Diedrich. (2008) Hormontherapie in den Wechseljahren. Der Gynäkologe 41:11, 858-864
CrossRef188
Miguel A. Hernán, Alvaro Alonso, Roger Logan, Francine Grodstein, Karin B. Michels, Walter C. Willett, JoAnn E. Manson, James M. Robins. (2008) Observational Studies Analyzed Like Randomized Experiments. Epidemiology 19:6, 766-779
CrossRef189
Jennifer A. Cann, Thomas C. Register, Michael R. Adams, Richard W. St. Clair, Mark A. Espeland, J. Koudy Williams. (2008) Timing of estrogen replacement influences atherosclerosis progression and plaque leukocyte populations in ApoE−/− mice. Atherosclerosis 201:1, 43-52
CrossRef190
Edoardo Casiglia, Valérie Tikhonoff, Sandro Caffi, Anna Bascelli, Laura Schiavon, Federica Guidotti, Mario Saugo, Martina Giacomazzo, Bortolo Martini, Alberto Mazza, Daniele DʼEste, Achille C Pessina. (2008) Menopause does not affect blood pressure and risk profile, and menopausal women do not become similar to men. Journal of Hypertension 26:10, 1983-1992
CrossRef191
U. Ravens. (2008) Hormonersatztherapie und kardiovaskuläre Erkrankungen. Der Kardiologe 2:5, 435-448
CrossRef192
Ross L. Prentice, Garnet L. Anderson. 2008. Women's Health Initiative: Statistical Aspects and Selected Early Results. .
CrossRef193
Shari S. Bassuk, JoAnn E. Manson. 2008. Women's Health Initiative Hormone Therapy Trials. .
CrossRef194
STANLEY J. BIRGE. (2008) Hormone Therapy and Stroke. Clinical Obstetrics and Gynecology 51:3, 581-591
CrossRef195
J.E. Pflumm, T. Pomykaj, M.P. Heintzen. (2008) Sekundärprävention nach Myokardinfarkt. Der Internist 49:9, 1052-1060
CrossRef196
Jennifer G. Robinson, Robert Wallace, Marian Limacher, Hong Ren, Barbara Cochrane, Sylvia Wassertheil-Smoller, Judith K. Ockene, Patricia L. Blanchette, Marcia G. Ko. (2008) Cardiovascular Risk in Women With Non-Specific Chest Pain (from the Women's Health Initiative Hormone Trials)†‡. The American Journal of Cardiology 102:6, 693-699
CrossRef197
NANETTE SANTORO. (2008) Symptoms of Menopause: Hot Flushes. Clinical Obstetrics and Gynecology 51:3, 539-548
CrossRef198
Klaas Heinemann, Alexander Rübig, Anja Strothmann, Gerard G. Nahum, Lothar A.J. Heinemann. (2008) Prevalence and Opinions of Hormone Therapy Prior to the Women's Health Initiative: A Multinational Survey on Four Continents. Journal of Women's Health 17:7, 1151-1166
CrossRef199
Howard N. Hodis, Wendy J. Mack. (2008) Postmenopausal Hormone Therapy and Cardiovascular Disease in Perspective. Clinical Obstetrics and Gynecology 51:3, 564-580
CrossRef200
Eliot A. Brinton, Howard N. Hodis, George R. Merriam, S. Mitchell Harman, Frederick Naftolin. (2008) Can menopausal hormone therapy prevent coronary heart disease?. Trends in Endocrinology & Metabolism 19:6, 206-212
CrossRef201
Sofia B Ahmed, Bruce F Culleton, Marcello Tonelli, Scott W Klarenbach, Jennifer M MacRae, Jianguo Zhang, Brenda R Hemmelgarn. (2008) Oral estrogen therapy in postmenopausal women is associated with loss of kidney function. Kidney International 74:3, 370-376
CrossRef202
José A. Barrabés. (2008) Función endotelial en la arteria que causa el infarto: ¿es importante la modalidad del tratamiento de reperfusión?. Revista Española de Cardiología 61:8, 797-799
CrossRef203
Michal Vrablik, Tomas Fait, Jan Kovar, Rudolf Poledne, Richard Ceska. (2008) Oral but not transdermal estrogen replacement therapy changes the composition of plasma lipoproteins. Metabolism 57:8, 1088-1092
CrossRef204
Paula S. Derry. (2008) Update on Hormones, Menopause, and Heart Disease: Evaluating Professional Responses to the Women's Health Initiative. Health Care for Women International 29:7, 720-737
CrossRef205
Dominik Rachoń, Tina Vortherms, Dana Seidlová-Wuttke, Wolfgang Wuttke. (2008) Effects of black cohosh extract on body weight gain, intra-abdominal fat accumulation, plasma lipids and glucose tolerance in ovariectomized Sprague–Dawley rats. Maturitas 60:3-4, 209-215
CrossRef206
Jacqueline Suk Danik, Nader Rifai, Julie E. Buring, Paul M. Ridker. (2008) Lipoprotein(a), Hormone Replacement Therapy, and Risk of Future Cardiovascular Events. Journal of the American College of Cardiology 52:2, 124-131
CrossRef207
A. M. Plotnikova, Z. T. Shulgau, T. M. Plotnikova, O. I. Aliev, T. G. Borovskaya. (2008) Hyperviscosity syndrome in ovariectomized rats. Bulletin of Experimental Biology and Medicine 146:1, 92-95
CrossRef208
Marc L’Hermite, Tommaso Simoncini, Sarah Fuller, Andrea Riccardo Genazzani. (2008) Could transdermal estradiol+progesterone be a safer postmenopausal HRT? A review. Maturitas 60:3-4, 185-201
CrossRef209
Remi Yoshikata, Yuko Miyahara, Yoshiko Onoe, Hiroya Okano, Hiroaki Ohta. (2008) Possible risk factor for postmenopausal women: Postprandial hypertriglyceridemia. Journal of Obstetrics and Gynaecology Research???-???
CrossRef210
E. Lokkegaard, A. H. Andreasen, R. K. Jacobsen, L. H. Nielsen, C. Agger, O. Lidegaard. (2008) Hormone therapy and risk of myocardial infarction: a national register study. European Heart Journal 29:21, 2660-2668
CrossRef211
M. V. Cohen, J. M. Downey. (2008) Oestrogen plays a permissive role in cardioprotection. Cardiovascular Research 79:3, 353-354
CrossRef212
JB Warren. (2008) Cholesterol—When Is Lower Better?. Clinical Pharmacology & Therapeutics 83:5, 777-780
CrossRef213
Tommaso Simoncini, Silvia Garibaldi, Xiao-Dong Fu, Silvia Pisaneschi, Silvia Begliuomini, Chiara Baldacci, Elena Lenzi, Lorenzo Goglia, Maria S. Giretti, Andrea R. Genazzani. (2008) Effects of phytoestrogens derived from red clover on atherogenic adhesion molecules in human endothelial cells. Menopause 15:3, 542-550
CrossRef214
M.O. Weickert, A.F.H. Pfeiffer. (2008) Geschlechtsspezifische Aspekte beim metabolischen Syndrom. Der Diabetologe 4:3, 182-188
CrossRef215
Richard D. Patten, Isaac Pourati, Mark J. Aronovitz, Alawi Alsheikh-Ali, Sarah Eder, Thomas Force, Michael E. Mendelsohn, Richard H. Karas. (2008) 17 Beta-Estradiol Differentially Affects Left Ventricular and Cardiomyocyte Hypertrophy Following Myocardial Infarction and Pressure Overload. Journal of Cardiac Failure 14:3, 245-253
CrossRef216
David H. Barlow. (2008) The Medical Management of Menopause. Annals of the New York Academy of Sciences 1127:1, 134-139
CrossRef217
(2008) Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. The Lancet 371:9622, 1417-1426
CrossRef218
Ross L. Prentice, Garnet L. Anderson. (2008) The Women's Health Initiative: Lessons Learned. Annual Review of Public Health 29:1, 131-150
CrossRef219
M. Ángeles Rosero Arenas, Esteban Rosero Arenas, M. Amparo Portaceli Armiñana, Miguel Ángel García García. (2008) Utilidad de los fitoestrógenos en la reducción de la presión arterial. Revisión sistemática y metaanálisis. Atención Primaria 40:4, 177-186
CrossRef220
Michael Proschan. (2008) Self-experimentation and web trials. CHANCE 21:1, 7-9
CrossRef221
Tjeerd P. van Staa, Cyrus Cooper, David Barlow, Hubert G.M. Leufkens. (2008) Individualizing the risks and benefits of postmenopausal hormone therapy. Menopause 15:2, 374-381
CrossRef222
Farida Sohrabji. (2008) Premenopausal oophorectomy and the risk for dementia. Women's Health 4:2, 127-131
CrossRef223
Jay Schulkin. (2008) Hormone Therapy, Dilemmas, Medical Decisions. The Journal of Law, Medicine & Ethics 36:1, 73-88
CrossRef224
Richard E Hedrick. (2008) Low-dose estradiol gel 0.1% for the treatment of vasomotor symptoms associated with menopause. Expert Review of Obstetrics & Gynecology 3:2, 155-162
CrossRef225
Bari Kaplan, Michael Hirsch, Dov Feldberg. 2008. Hormone replacement therapy and diabetes. , 458-465.
CrossRef226
Stefan Mathis, Gerald Gartlehner. (2008) Kohortenstudien. Wiener Medizinische Wochenschrift 158:5-6, 174-179
CrossRef227
Majoie Hemelaar, Peter Kenemans, C. Erik Hack, Christine Klipping, Marius J. van der Mooren. (2008) Hemostatic markers in healthy postmenopausal women during intranasal and oral hormone therapy. Menopause 15:2, 248-255
CrossRef228
Cesar E. Fernandes, Luciano M. Pompei, Rogério B. Machado, José Arnaldo S. Ferreira, Nilson R. Melo, Sergio Peixoto. (2008) Effects of estradiol and norethisterone on lipids, insulin resistance and carotid flow. Maturitas 59:3, 249-258
CrossRef229
Rosemary Theroux. (2008) Postmenopausal Hormone Use: What Does the Latest Evidence Show?. Nursing for Women's Health 12:1, 56-61
CrossRef230
George Davey Smith. (2008) Assessing Intrauterine Influences on Offspring Health Outcomes: Can Epidemiological Studies Yield Robust Findings?. Basic & Clinical Pharmacology & Toxicology 102:2, 245-256
CrossRef231
Mi-Kyung Park, Mee-ra Rhyu, Byung-Koo Yoon, Hyeok yi Kwon, Siyoul Jang, Young Joo Lee. (2008) Modulation of the genomic estrogen receptor pathway by water extracts of Cirsium japonicum. Archives of Pharmacal Research 31:2, 225-230
CrossRef232
William Cahoon, Maureen P. Flattery. (2008) ACC/AHA Non-ST Elevation Myocardial Infarction Guidelines' Revision 2007: Implications for Nursing Practice. Progress in Cardiovascular Nursing 23:1, 53-56
CrossRef233
MF Bordet, A Colas, P Marijnen, JL Masson, M Trichard. (2008) Treating hot flushes in menopausal women with homeopathic treatment–Results of an observational study. Homeopathy 97:1, 10-15
CrossRef234
&NA;. (2008) Low-Dose Transdermal Estrogens. Obstetrics & Gynecology 111:1, 209-211
CrossRef235
Glen E Cooke. (2008) Post-menopausal hormone therapy and cardiovascular events: a new paradigm based on pharmacogenetics?. Future Cardiology 4:1, 19-21
CrossRef236
Lynnette Leidy Sievert, Matilda Saliba, David Reher, Amina Sahel, Doris Hoyer, Mary Deeb, Carla Makhlouf Obermeyer. (2008) The medical management of menopause: A four-country comparison care in urban areas. Maturitas 59:1, 7-21
CrossRef237
William B. White, Vladimir Hanes, Madhavi Mallareddy, Vijay Chauhan. (2008) Effects of the hormone therapy, drospirenone and 17-beta estradiol, on early morning blood pressure in postmenopausal women with hypertension. Journal of the American Society of Hypertension 2:1, 20-27
CrossRef238
JoAnn V. Pinkerton, Alan C. Dalkin. (2007) Combination therapy for treatment of osteoporosis: A review. American Journal of Obstetrics and Gynecology 197:6, 559-565
CrossRef239
Joseph Gligorov, Kathleen Pritchard, Paul Goss. (2007) Adjuvant and extended adjuvant use of aromatase inhibitors: Reducing the risk of recurrence and distant metastasis. The Breast 16, 1-9
CrossRef240
David F. Ransohoff. (2007) How to improve reliability and efficiency of research about molecular markers: roles of phases, guidelines, and study design. Journal of Clinical Epidemiology 60:12, 1205-1219
CrossRef241
Rebecca D. Jackson, Shubhangi Shidham. (2007) The role of hormone therapy and calcium plus vitamin D for reduction of bone loss and risk for fractures: Lessons learned from the women’s health initiative. Current Osteoporosis Reports 5:4, 153-159
CrossRef242
Adolfo Díez Pérez. (2007) Aspectos terapéuticos de la osteoporosis. Medicina Clínica 129:20, 773-774
CrossRef243
Marieke O. Verhoeven, Majoie Hemelaar, Tom Teerlink, Peter Kenemans, Marius J. van der Mooren. (2007) Effects of intranasal versus oral hormone therapy on asymmetric dimethylarginine in healthy postmenopausal women: A randomized study. Atherosclerosis 195:1, 181-188
CrossRef244
Carlos A. Vaz Fragoso, Thomas M. Gill. (2007) Sleep Complaints in Community-Living Older Persons: A Multifactorial Geriatric Syndrome. Journal of the American Geriatrics Society 55:11, 1853-1866
CrossRef245
Frank Z. Stanczyk. (2007) Parenteral versus oral treatment of postmenopausal women with estrogen. Menopause 14:6, 968-970
CrossRef246
Rhonda Bentley-Lewis, Katherine Koruda, Ellen W Seely. (2007) The metabolic syndrome in women. Nature Clinical Practice Endocrinology & Metabolism 3:10, 696-704
CrossRef247
Emre Seli, Ozlem Guzeloglu-Kayisli, Umit A. Kayisli, Gulnur Kizilay, Aydin Arici. (2007) Estrogen increases apoptosis in the arterial wall in a murine atherosclerosis model. Fertility and Sterility 88:4, 1190-1196
CrossRef248
Hung Huynh, Nicolas Servant, Lorraine E. Chalifour. (2007) Ubiquinol–cytochrome- c reductase 7.2 kDa protein of mitochondrial complex III is steroid-responsive and increases in cardiac hypertrophy and hypertension. Canadian Journal of Physiology and Pharmacology 85:10, 986-996
CrossRef249
Lu Chen, Yuan Liu, Bota Cui, Qiongyu Mi, Yan Huang, Leming Fan, Qi Chen, James Tang, Albert Ferro, Yong Ji. (2007) 17?-OESTRADIOL PARTIALLY ATTENUATES THE INHIBITION OF NITRIC OXIDE SYNTHASE-3 BY ADVANCED GLYCATION END-PRODUCTS IN HUMAN PLATELETS. Clinical and Experimental Pharmacology and Physiology 34:10, 972-978
CrossRef250
Anne T. Berg. (2007) Hypotheses, tests, methods, and innovation: The balancing act in research. Epilepsia 0:0, 070916052732004-???
CrossRef251
F. Reed Johnson, Semra Özdemir, Brett Hauber, Teresa L. Kauf. (2007) Women's Willingness to Accept Perceived Risks for Vasomotor Symptom Relief. Journal of Women's Health 16:7, 1028-1040
CrossRef252
Howard N. Hodis, Wendy J. Mack. (2007) Postmenopausal hormone therapy in clinical perspective. Menopause 14:5, 944-957
CrossRef253
Paola Bertuccio, Alessandra Tavani, Silvano Gallus, Eva Negri, Carlo La Vecchia. (2007) Menstrual and reproductive factors and risk of non-fatal acute myocardial infarction in Italy. European Journal of Obstetrics & Gynecology and Reproductive Biology 134:1, 67-72
CrossRef254
Steven J. Russell, C. Ronald Kahn. (2007) Endocrine regulation of ageing. Nature Reviews Molecular Cell Biology 8:9, 681-691
CrossRef255
A.O. Mueck, H. Seeger. (2007) Kardiovaskuläre Risiken unter HRT in der Postmenopause. Gynäkologische Endokrinologie 5:3, 120-126
CrossRef256
Dominik Rachoń, Tina Vortherms, Dana Seidlovä-Wuttke, Wolfgang Wuttke. (2007) Effects of dietary equol on body weight gain, intra-abdominal fat accumulation, plasma lipids, and glucose tolerance in ovariectomized Sprague-Dawley rats. Menopause 14:5, 925-932
CrossRef257
Peter Alexandersen, Morten A Karsdal, Claus Christiansen. (2007) Hormone replacement as the first-line prevention for postmenopausal osteoporosis. Expert Review of Obstetrics & Gynecology 2:5, 689-700
CrossRef258
Bhavna Mohandas, Jawahar L Mehta. (2007) Lessons from hormone replacement therapy trials for primary prevention of cardiovascular disease. Current Opinion in Cardiology 22:5, 434-442
CrossRef259
Sara Bleich, Robert Blendon, Alyce Adams. (2007) Trust in Scientific Experts on Obesity: Implications for Awareness and Behavior Change. Obesity 15:8, 2145-2156
CrossRef260
Jeffrey L. Anderson, Cynthia D. Adams, Elliott M. Antman, Charles R. Bridges, Robert M. Califf, Donald E. Casey, William E. Chavey, Francis M. Fesmire, Judith S. Hochman, Thomas N. Levin, A. Michael Lincoff, Eric D. Peterson, Pierre Theroux, Nanette Kass Wenger, R. Scott Wright, Sidney C. Smith, Alice K. Jacobs, Cynthia D. Adams, Jeffrey L. Anderson, Elliott M. Antman, Jonathan L. Halperin, Sharon A. Hunt, Harlan M. Krumholz, Frederick G. Kushner, Bruce W. Lytle, Rick Nishimura, Joseph P. Ornato, Richard L. Page, Barbara Riegel. (2007) ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction. Journal of the American College of Cardiology 50:7, e1-e157
CrossRef261
Susan WS Leung, Hwee Teoh, Wendy Keung, Ricky YK Man. (2007) NON-GENOMIC VASCULAR ACTIONS OF FEMALE SEX HORMONES: PHYSIOLOGICAL IMPLICATIONS AND SIGNALLING PATHWAYS. Clinical and Experimental Pharmacology and Physiology 34:8, 822-826
CrossRef262
Barbara Dehn. (2007) Care of the menopausal patient: A nurse practitioner?s view. Journal of the American Academy of Nurse Practitioners 19:8, 427-437
CrossRef263
&NA;. (2007) Angeliq for Treatment of Menopausal Symptoms. Obstetrics & Gynecology 110:1, 177-178
CrossRef264
Myl??ne Aubertin-Leheudre, Christine Lord, Abdelouahed Khalil, Isabelle J. Dionne. (2007) Effect of 6 months of exercise and isoflavone supplementation on clinical cardiovascular risk factors in obese postmenopausal women. Menopause 14:4, 624-629
CrossRef265
W Dana Flanders, Mitchel Klein. (2007) Properties of 2 Counterfactual Effect Definitions of a Point Exposure. Epidemiology 18:4, 453-460
CrossRef266
Ioannis S. Benetos, George C. Babis, Aristides B. Zoubos, Vassiliki Benetou, Panayotis N. Soucacos. (2007) Factors affecting the risk of hip fractures. Injury 38:7, 735-744
CrossRef267
Eberhard Windler, Birgit-Christiane Zyriax, Britta Eidenmüller, Heiner Boeing. (2007) Hormone replacement therapy and risk for coronary heart disease. Maturitas 57:3, 239-246
CrossRef268
Richard L. Tannen, Mark G. Weiner, Dawei Xie, Kurt Barnhart. (2007) A simulation using data from a primary care practice database closely replicated the women's health initiative trial. Journal of Clinical Epidemiology 60:7, 686-695
CrossRef269
Mendelsohn, Michael E., Karas, Richard H., . (2007) HRT and the Young at Heart. New England Journal of Medicine 356:25, 2639-2641
Full Text270
Micol S Rothman, Margaret E Wierman. (2007) Testosterone and cardiovascular disease in men. Aging Health 3:3, 375-381
CrossRef271
Peter Y. Liu, Brendon J. Yee, Craig L. Phillips, Ronald R. Grunstein. (2007) Sleep Apnea and Neuroendocrine Function. Sleep Medicine Clinics 2:2, 225-236
CrossRef272
Michael Cirigliano. (2007) Bioidentical Hormone Therapy: A Review of the Evidence. Journal of Women's Health 16:5, 600-631
CrossRef273
Martin K.C. Ng. (2007) New Perspectives on Mars and Venus: Unravelling the Role of Androgens in Gender Differences in Cardiovascular Biology and Disease. Heart, Lung and Circulation 16:3, 185-192
CrossRef274
M Nilsson, I Dahlman, M Rydén, E A Nordström, J-Å Gustafsson, P Arner, K Dahlman-Wright. (2007) Oestrogen receptor α gene expression levels are reduced in obese compared to normal weight females. International Journal of Obesity 31:6, 900-907
CrossRef275
Leslie Spangler, Katherine M. Newton, Louis C. Grothaus, Susan D. Reed, Kelly Ehrlich, Andrea Z. LaCroix. (2007) The effects of black cohosh therapies on lipids, fibrinogen, glucose and insulin. Maturitas 57:2, 195-204
CrossRef276
Stijn Blot, Pieter Depuydt. (2007) Antibiotic therapy for community-acquired pneumonia with septic shock: Follow the guidelines*. Critical Care Medicine 35:6, 1617-1618
CrossRef277
Stephen Coleman. (2007) testing theories with qualitative and quantitative predictions. European Political Science 6:2, 124-133
CrossRef278
Barry G. Saver, David Gustafson, Thomas R. Taylor, Robert P. Hawkins, Nancy F. Woods, Susan Dinauer, Susan Casey, Aileen MacLaren-Loranger. (2007) A tale of two studies: The importance of setting, subjects and context in two randomized, controlled trials of a web-based decision support for perimenopausal and postmenopausal health decisions. Patient Education and Counseling 66:2, 211-222
CrossRef279
Howard N. Hodis, Wendy J. Mack. (2007) Postmenopausal hormone therapy and cardiovascular disease: Making sense of the evidence. Current Cardiovascular Risk Reports 1:2, 138-147
CrossRef280
Thomas B. Clarkson. (2007) Estrogen effects on arteries vary with stage of reproductive life and extent of subclinical atherosclerosis progression. Menopause 14:3, 373-384
CrossRef281
Hong He, Falin Yang, Xianxi Liu, Xianwei Zeng, Qin Hu, Qing Zhu, Bing Tu. (2007) Sex hormone ratio changes in men and postmenopausal women with coronary artery disease. Menopause 14:3, 385-390
CrossRef282
David F. Archer. (2007) Drospirenone, a progestin with added value for hypertensive postmenopausal women. Menopause 14:3, 352-354
CrossRef283
Attila Molvarec, Bálint Nagy, Margit Kovács, Szilvia Walentin, Éva Imreh, János Rigó, János Szalay, George Füst, Zoltán Prohászka, István Karádi. (2007) Lipid, haemostatic and inflammatory variables in relation to the estrogen receptor α (ESR1) PvuII and XbaI gene polymorphisms. Clinica Chimica Acta 380:1-2, 157-164
CrossRef284
David F. Archer. (2007) Endometrial bleeding during hormone therapy: The effect of progestogens. Maturitas 57:1, 71-76
CrossRef285
Jeffrey J. Link, Anand Rohatgi, James A. de Lemos. (2007) HDL Cholesterol: Physiology, Pathophysiology, and Management. Current Problems in Cardiology 32:5, 268-314
CrossRef286
Henry G. Burger. (2007) WHI risks: Any relevance to menopause management?. Maturitas 57:1, 6-10
CrossRef287
John C. Stevenson. (2007) HRT and the primary prevention of cardiovascular disease. Maturitas 57:1, 31-34
CrossRef288
Marieke O. Verhoeven, Tom Teerlink, Peter Kenemans, Sonja D. Zuijdgeest-van Leeuwen, Marius J. van der Mooren. (2007) Effects of a supplement containing isoflavones and Actaea racemosa L. on asymmetric dimethylarginine, lipids, and C-reactive protein in menopausal women. Fertility and Sterility 87:4, 849-857
CrossRef289
Thomas Dayspring, Gregory Pokrywka. (2007) Pharmacotherapeutic decisions in menopausal women with cardiovascular risk. Future Lipidology 2:2, 197-210
CrossRef290
D COSTAGLIOLA. (2007) Observation versus intervention in the evaluation of drugs: the story of hormone replacement therapy. Comptes Rendus Biologies 330:4, 347-355
CrossRef291
Marieke O. Verhoeven, Tom Teerlink, Peter Kenemans, Tatjana E. Vogelvang, Marius J. van der Mooren. (2007) Effects on asymmetric dimethylarginine of HMR 3339, a novel selective estrogen receptor modulator. Menopause 14:2, 235-242
CrossRef292
Andrew P. Miller, Dongqi Xing, Wenguang Feng, Marion Fintel, Yiu-Fai Chen, Suzanne Oparil. (2007) Aged rats lose vasoprotective and anti-inflammatory actions of estrogen in injured arteries. Menopause 14:2, 251-260
CrossRef293
P.H.M. van de Weijer, Lars-Åke Mattsson, Olavi Ylikorkala. (2007) Benefits and risks of long-term low-dose oral continuous combined hormone therapy. Maturitas 56:3, 231-248
CrossRef294
Giuseppe M.C. Rosano, Otavio Gebara, Imad Sheiban, Antonello Silvestri, Mauricio Wajngarten, Cristiana Vitale, Jose Aldrighi, Antonio F. Ramires, Massimo Fini, Giuseppe Mercuro. (2007) Acute administration of 17β-estradiol reduces endothelin-1 release during pacing-induced ischemia. International Journal of Cardiology 116:1, 34-39
CrossRef295
Sandra Lewis. (2007) Do endocrine treatments for breast cancer have a negative impact on lipid profiles and cardiovascular risk in postmenopausal women?. American Heart Journal 153:2, 182-188
CrossRef296
Michelle P. Warren. (2007) Historical Perspectives in Postmenopausal Hormone Therapy: Defining the Right Dose and Duration. Mayo Clinic Proceedings 82:2, 219-226
CrossRef297
M. P. Warren. (2007) Historical Perspectives in Postmenopausal Hormone Therapy: Defining the Right Dose and Duration. Mayo Clinic Proceedings 82:2, 219-226
CrossRef298
Ki Ok Han. (2007) Postmenopausal Hormone Therapy Up-to-date. Journal of Korean Endocrine Society 22:5, 317
CrossRef299
Kelley K. Pettee, Andrea M. Kriska, B. Delia Johnson, Molly B. Conroy, Rachel H. Mackey, Trevor J. Orchard, Lewis H. Kuller. (2007) The relationship between physical activity and lipoprotein subclasses in postmenopausal women. Menopause 14:1, 115-122
CrossRef300
Apurva Motivala, Bertram Pitt. (2007) Drospirenone for Oral Contraception and Hormone Replacement Therapy. Drugs 67:5, 647-655
CrossRef301
David F. Archer. (2007) Medical decisions regarding hormone therapy for menopausal women are significantly influenced by the media. Pharmacoepidemiology and Drug Safety 16:1, 28-31
CrossRef302
Luigi Gennari, Daniela Merlotti, Fabrizio Valleggi, Giuseppe Martini, Ranuccio Nuti. (2007) Selective Estrogen Receptor Modulators for Postmenopausal Osteoporosis. Drugs & Aging 24:5, 361-379
CrossRef303
(2007) Traitement médicamenteux du diabète de type 2recommandation de bonne pratique. Diabetes & Metabolism 33:1, S26-S105
CrossRef304
Gordon DO Lowe. (2007) Update on the cardiovascular risks of hormone replacement therapy. Women's Health 3:1, 87-97
CrossRef305
R. Tissier, X. Waintraub, N. Couvreur, M. Gervais, P. Bruneval, C. Mandet, R. Zini, B. Enriquez, A. Berdeaux, B. Ghaleh. (2007) Pharmacological postconditioning with the phytoestrogen genistein. Journal of Molecular and Cellular Cardiology 42:1, 79-87
CrossRef306
Brian W. Whitcomb, Maura K. Whiteman, Patricia Langenberg, Jodi A. Flaws, William A. Romani. (2007) Physical Activity And Risk of Hot Flashes among Women in Midlife. Journal of Women's Health 16:1, 124-133
CrossRef307
Michael H Davidson. (2007) Rosuvastatin in Elderly Patients. Drugs & Aging 24:11, 933-944
CrossRef308
Suman Sood, Steven Stein, Barbara A. Konkle. 2007. Thrombotic Risk of Contraceptives and Other Hormonal Therapies. , 567-580.
CrossRef309
SM Bakker, JAH Eekhof, ALM Lagro-Jansen, A Knuistingh Neven. (2006) Opvliegers. Huisarts en Wetenschap 49:13, 951-956
CrossRef310
Tord Naessen, Kenny Rodriguez-Macias. (2006) Menopausal estrogen therapy counteracts normal aging effects on intima thickness, media thickness and intima/media ratio in carotid and femoral arteries. Atherosclerosis 189:2, 387-392
CrossRef311
Ruth McPherson, Jim Shepherd. (2006) Peering through the darkened glass: success and disappointment in the management of cardiovascular risk. Current Opinion in Lipidology 17:6, 615-618
CrossRef312
Henri Rozenbaum. (2006) How to evaluate the risk-benefit ratio of the low-dose hormone replacement therapy?. The Journal of Steroid Biochemistry and Molecular Biology 102:1-5, 256-260
CrossRef313
J.F. Arnal, V. Douin-Echinard, L. Brouchet, F. Tremollières, H. Laurell, F. Lenfant, A.P. Gadeau, J.C. Guery, P. Gourdy. (2006) Understanding the oestrogen action in experimental and clinical atherosclerosis. Fundamental and Clinical Pharmacology 20:6, 539-548
CrossRef314
Debbie A Lawlor, George Davey Smith. (2006) Cardiovascular risk and hormone replacement therapy. Current Opinion in Obstetrics and Gynecology 18:6, 658-665
CrossRef315
J BLAKE. (2006) Menopause: evidence-based practice. Best Practice & Research Clinical Obstetrics & Gynaecology 20:6, 799-839
CrossRef316
Ann M. Voda, Carol A. Ashton. (2006) Fallout from the Women’s Health Study: A Short-lived Vindication for Feminists and the Resurrection of Hormone Therapies. Sex Roles 54:5-6, 401-411
CrossRef317
Kerrie L. Moreau, Kathleen M. Gavin, Angela E. Plum, Douglas R. Seals. (2006) Oxidative stress explains differences in large elastic artery compliance between sedentary and habitually exercising postmenopausal women. Menopause 13:6, 951-958
CrossRef318
Suzanne Oparil. (2006) Women and Hypertension. Cardiology in Review 14:6, 267-275
CrossRef319
Chrishan S. Samuel, Xiao-Jun Du, Ross A.D. Bathgate, Roger J. Summers. (2006) ‘Relaxin’ the stiffened heart and arteries: The therapeutic potential for relaxin in the treatment of cardiovascular disease. Pharmacology & Therapeutics 112:2, 529-552
CrossRef320
Santiago Palacios, Jean-Michel Foidart, Andrea R. Genazzani. (2006) Advances in hormone replacement therapy with drospirenone, a unique progestogen with aldosterone receptor antagonism. Maturitas 55:4, 297-307
CrossRef321
A. F. B. Kernohan, N. Sattar, T. Hilditch, S. J. Cleland, M. Small, M. A. Lumsden, J. M. C. Connell, J. R. Petrie. (2006) Effects of low-dose continuous combined hormone replacement therapy on glucose homeostasis and markers of cardiovascular risk in women with type
2 diabetes. Clinical Endocrinology 0:0, 061020035253001-???
CrossRef322
Vera Bittner. 2006. Women and Coronary Heart Disease. , 689-720.
CrossRef323
Virginia Massheimer, Nélida Polini, Cristina Alvarez, Silvia Benozzi, María Belén Rauschemberger, Juana Sellés. (2006) Signal transduction pathways involved in non-genomic action of estrone on vascular tissue. Steroids 71:10, 857-864
CrossRef324
Tommaso Simoncini, Antonella Caruso, Silvia Garibaldi, Xiao-Dong Fu, Maria Silvia Giretti, Chiara Baldacci, Camila Scorticati, Letizia Fornari, Paolo Mannella, Andrea Riccardo Genazzani. (2006) Activation of Nitric Oxide Synthesis in Human Endothelial Cells Using Nomegestrol Acetate. Obstetrics & Gynecology 108:4, 969-978
CrossRef325
Peter F. Schnatz. (2006) Hormonal Therapy: Does It Increase or Decrease Cardiovascular Risk?. Obstetrical & Gynecological Survey 61:10, 673-681
CrossRef326
Giovanni Scambia, Daniela Gallo. (2006) The role of phytochemicals in menopause. Menopause 13:5, 724-726
CrossRef327
P. NEVEN, I. VERGOTE, F. AMANT, P. BERTELOOT, E. de JONGE, C. DE ROP, P. DE SUTTER, A. MAKAR, J. VAN GINDERACHTER. (2006) Endocrine Treatment and Prevention of Breast and Gynecological Cancers Vth International Symposium of the Flemish Gynecological Oncology Group, January 26?28, 2006. International Journal of Gynecological Cancer 16:s2, 479-491
CrossRef328
S. R. Salpeter, J. M. E. Walsh, T. M. Ormiston, E. Greyber, N. S. Buckley, E. E. Salpeter. (2006) Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes, Obesity and Metabolism 8:5, 538-554
CrossRef329
Marilee Benore-Parsons. (2006) A course designed for undergraduate biochemistry students to learn about cultural diversity issues. Biochemistry and Molecular Biology Education 34:5, 326-331
CrossRef330
Piret Veerus, Sirpa-Liisa Hovi, Krista Fischer, Mati Rahu, Matti Hakama, Elina Hemminki. (2006) Results from the Estonian postmenopausal hormone therapy trial [ISRCTN35338757]. Maturitas 55:2, 162-173
CrossRef331
Eberhard Nieschlag. (2006) Testosterone treatment comes of age: new options for hypogonadal men. Clinical Endocrinology 65:3, 275-281
CrossRef332
(2006) Guía sobre el manejo de la angina estable. Versión resumida. Revista Española de Cardiología 59:9, 919-970
CrossRef333
Luigi Gennari, Daniela Merlotti, Giuseppe Martini, Ranuccio Nuti. (2006) Lasofoxifene: a third-generation selective estrogen receptor modulator for the prevention and treatment of osteoporosis. Expert Opinion on Investigational Drugs 15:9, 1091-1103
CrossRef334
Anthony A. Bavry, Deepak L. Bhatt. (2006) Interpreting observational studies—look before you leap. Journal of Clinical Epidemiology 59:8, 763-764
CrossRef335
Hugo Maia, Marco Aurélio Albernaz, Edmund Chada Baracat, Ione Cristina Barbosa, Ronald Bossemeyer, Alberto Hernández Bueno, Oscar González Campos, Sebastián Carranza-Lira, Pedro Figueroa Casas, Álvaro Monterrosa Castro, Geraldo Rodrigues de Lima, Nilson R. de Melo, César Eduardo Fernandes, Javier Santos González, Francisco Espinosa Larrañaga, Néstor Siseles, Alfonso Murillo Uribe, Rafael Molina Vilchez. (2006) Latin American position on the current status of hormone therapy during the menopausal transition and thereafter. Maturitas 55:1, 5-13
CrossRef336
Aman Buzdar, Rowan Chlebowski, Jack Cuzick, Sean Duffy, John Forbes, Walter Jonat, Peter Ravdin. (2006) Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer. Current Medical Research and Opinion 22:8, 1575-1585
CrossRef337
Xiao-Jun Du, Lu Fang, Helen Kiriazis. (2006) Sex dimorphism in cardiac pathophysiology: Experimental findings, hormonal mechanisms, and molecular mechanisms. Pharmacology & Therapeutics 111:2, 434-475
CrossRef338
Piret Veerus, Krista Fischer, Sirpa-Liisa Hovi, Matti Hakama, Mati Rahu, Elina Hemminki. (2006) Postmenopausal hormone therapy increases use of health services: Experience from the Estonian Postmenopausal Hormone Therapy Trial [ISRCTN35338757]. American Journal of Obstetrics and Gynecology 195:1, 62-71
CrossRef339
Martin Wehling, Armin Schultz, Ralf Lösel. (2006) Nongenomic actions of estrogens: Exciting opportunities for pharmacology. Maturitas 54:4, 321-326
CrossRef340
Michelle P. Warren, Abigail Chua. (2006) Appropriate use of estrogen replacement therapy in adolescents and young adults with Turner syndrome and hypopituitarism in light of the Women’s Health Initiative. Growth Hormone & IGF Research 16, 98-102
CrossRef341
Marianne Canonico, Céline Straczek, Emmanuel Oger, Geneviève Plu-Bureau, Pierre-Yves Scarabin. (2006) Postmenopausal hormone therapy and cardiovascular disease: An overview of main findings. Maturitas 54:4, 372-379
CrossRef342
May Wahab, Farook Al-Azzawi. (2006) Current state of hormone replacement therapy: the case for using trimegestone. Women's Health 2:4, 539-550
CrossRef343
&NA;. (2006) Management of osteoporosis in postmenopausal women. Menopause 13:3, 340-367
CrossRef344
Glenn R Cunningham. (2006) Testosterone replacement therapy for late-onset hypogonadism. Nature Clinical Practice Urology 3:5, 260-267
CrossRef345
Mark Naunton, Asmar F. Y. Al Hadithy, Jacobus R. B. J. Brouwers, David F. Archer. (2006) Estradiol gel. Menopause 13:3, 517-527
CrossRef346
Shelagh K. Genuis. (2006) Exploring the role of medical and consumer literature in the diffusion of information related to hormone therapy for menopausal women. Journal of the American Society for Information Science and Technology 57:7, 974-988
CrossRef347
S. D. Braun, R. H. Strasser. (2006) Herz-Kreislauf-Erkrankungen. Der Gynäkologe 39:5, 354-361
CrossRef348
Roger A. Lobo. (2006) What is the effect of estrogen on blood pressure after menopause?. Menopause 13:3, 331-333
CrossRef349
Shweta Kaushik, Jie Jin Wang, Paul Mitchell. (2006) Retinal Vessel Diameter. Ophthalmology 113:5, 886-887.e1
CrossRef350
Farook Al-Azzawi, John Thompson, John Stevenson. (2006) Which progestogen is more likely to increase the risk of fatal myocardial infarction: A combination of epidemiological and trial evidence. Maturitas 54:2, 154-163
CrossRef351
G. G. Schwartz, W. J. Blot. (2006) Vitamin D Status and Cancer Incidence and Mortality: Something New Under the Sun. JNCI Journal of the National Cancer Institute 98:7, 428-430
CrossRef352
Majoie Hemelaar, Peter Kenemans, Lut de Bie, Peter H.M. van de Weijer, Marius J. van der Mooren. (2006) Intranasal continuous combined 17β-estradiol/norethisterone therapy improves the lipid profile in healthy postmenopausal women. Fertility and Sterility 85:4, 979-988
CrossRef353
Brian A. McDonnell, Leo B. Twiggs. (2006) Hormone Replacement Therapy in Endometrial Cancer Survivors. Journal of Lower Genital Tract Disease 10:2, 92-101
CrossRef354
Shelley R. Salpeter, Judith M. E. Walsh, Elizabeth Greyber, Edwin E. Salpeter. (2006) BRIEF REPORT: Coronary Heart Disease Events Associated with Hormone Therapy in Younger and Older Women. A Meta-Analysis. Journal of General Internal Medicine 21:4, 363-366
CrossRef355
Henry G. BURGER. (2006) Hormone therapy in the WHI era. The Australian and New Zealand Journal of Obstetrics and Gynaecology 46:2, 84-91
CrossRef356
Sophia N. Kalantaridou, Katerina K. Naka, Aris Bechlioulis, Antonis Makrigiannakis, Lampros Michalis, George P. Chrousos. (2006) Premature ovarian failure, endothelial dysfunction and estrogen–progestogen replacement. Trends in Endocrinology & Metabolism 17:3, 101-109
CrossRef357
Cairu Li, Gunnar Engström, Bo Hedblad, Göran Berglund, Lars Janzon. (2006) Risk of stroke and hormone replacement therapy. Maturitas 54:1, 11-18
CrossRef358
Pamela N Munster. (2006) Arzoxifene: the development and clinical outcome of an ideal SERM. Expert Opinion on Investigational Drugs 15:3, 317-326
CrossRef359
Matthew N. Bartels, Jonathan H. Whiteson, Augusta S. Alba, Heakyung Kim. (2006) Cardiopulmonary Rehabilitation and Cancer Rehabilitation. 1. Cardiac Rehabilitation Review. Archives of Physical Medicine and Rehabilitation 87:3, 46-56
CrossRef360
Jose Ness, Wilbert S. Aronow. (2006) Prevalence and Causes of Persistent Use of Hormone Replacement Therapy Among Postmenopausal Women: A Follow-Up Study. American Journal of Therapeutics 13:2, 109-112
CrossRef361
Suzette M Evans, Richard W Foltin. (2006) Exogenous Progesterone Attenuates the Subjective Effects of Smoked Cocaine in Women, but not in Men. Neuropsychopharmacology 31:3, 659-674
CrossRef362
Serkalem Demissie, L. Adrienne Cupples, Amanda M. Shearman, Kristen M. Gruenthal, Inga Peter, Christopher H. Schmid, Richard H. Karas, David E. Housman, Michael E. Mendelsohn, Jose M. Ordovas. (2006) Estrogen receptor-α variants are associated with lipoprotein size distribution and particle levels in women: The Framingham Heart Study. Atherosclerosis 185:1, 210-218
CrossRef363
Fränzel J.B. van Duijnhoven, Carla H. van Gils, Irene D. Bezemer, Petra H.M. Peeters, Yvonne T. van der Schouw, Diederick E. Grobbee. (2006) Use of hormones in the menopausal transition period in the Netherlands between 1993 and 1997. Maturitas 53:4, 462-475
CrossRef364
Bruce R. Carr, Naveed Khan, Beverley Adams-Huet, Nirupama Kakarla, Jon C. Havelock, Jennifer Gell. (2006) Effect of vitamin E supplementation with and without hormone therapy on circulatory inflammatory markers in postmenopausal women. Fertility and Sterility 85:3, 667-673
CrossRef365
Gazi Yildirim, Semih Tugrul, Hüsamettin Uslu, Oya Pekin, Sadiye Eren. (2006) Effects of two different regimens of continuous hormone replacement therapy on endometrial histopathology and postmenopausal uterine bleeding. Archives of Gynecology and Obstetrics 273:5, 268-273
CrossRef366
Jose Ness, Wilbert S. Aronow, Gwen Beck. (2006) Menopausal symptoms after cessation of hormone replacement therapy. Maturitas 53:3, 356-361
CrossRef367
M. O. VERHOEVEN, M. HEMELAAR, M. J. VAN DER MOOREN, P. KENEMANS, T. TEERLINK. (2006) Oral, more than transdermal, oestrogen therapy lowers asymmetric dimethylarginine in healthy postmenopausal women: a randomized, placebo-controlled study. Journal of Internal Medicine 259:2, 199-208
CrossRef368
M. Birkhäuser. (2006) Klinische Bedeutung von gestagenen Partialwirkungen. Gynäkologische Endokrinologie 4:1, 52-64
CrossRef369
Dianna J Magliano, Sophie L Rogers, Michael J Abramson, Andrew M Tonkin. (2006) Systematic review: Hormone therapy and cardiovascular disease: a systematic review and meta-analysis. BJOG: An International Journal of Obstetrics & Gynaecology 113:1, 5-14
CrossRef370
Helen L Jeanes, Payong Wanikiat, Isam Sharif, Gillian A Gray. (2006) Medroxyprogesterone acetate inhibits the cardioprotective effect of estrogen in experimental ischemia-reperfusion injury. Menopause 13:1, 80-86
CrossRef371
Rachael L. Fleurence, Cynthia P. Iglesias, David J. Torgerson. (2006) Economic evaluations of interventions for the prevention and treatment of osteoporosis: a structured review of the literature. Osteoporosis International 17:1, 29-40
CrossRef372
Tatjana El??ne Vogelvang, Marius Jan van der Mooren, Velja Mijatovic, Peter Kenemans. (2006) Emerging Selective Estrogen Receptor Modulators. Drugs 66:2, 191-221
CrossRef373
Jürgen Geisler, Per E. Lønning. (2006) Aromatase inhibitors as adjuvant treatment of breast cancer. Critical Reviews in Oncology/Hematology 57:1, 53-61
CrossRef374
JoAnn E Manson, Shari S Bassuk, S Mitchell Harman, Eliot A Brinton, Marcelle I Cedars, Rogerio Lobo, George R Merriam, Virginia M Miller, Frederick Naftolin, Nanette Santoro. (2006) Postmenopausal hormone therapy: new questions and the case for new clinical trials. Menopause 13:1, 139-147
CrossRef375
Cynthia M Carlsson. (2006) Homocysteine Lowering with Folic Acid and Vitamin B Supplements. Drugs & Aging 23:6, 491-502
CrossRef376
Denise M. Boudreau, Diana S. M. Buist, Carolyn M. Rutter, Paul A. Fishman, Kevin R. Beverly, Stephen Taplin. (2006) Impact of Hormone Therapy on False-Positive Recall and Costs Among Women Undergoing Screening Mammography. Medical Care 44:1, 62-69
CrossRef377
Daniela Gallo, Gian Franco Zannoni, Enrica Martinelli, Cristiano Ferlini, Manuela Fabrizi, Antonella Riva, Paolo Morazzoni, Ezio Bombardelli, Giovanni Scambia. (2006) Estradiol and phytoestrogens differently influence the rodent postmenopausal mammary gland. Menopause 13:1, 72-79
CrossRef378
Jon Ledlie. (2006) Point of View: Response. Spine 31:1, E1-E3
CrossRef379
Andrew H Briggs, Adrian R Levy. (2006) Pharmacoeconomics and Pharmacoepidemiology. PharmacoEconomics 24:11, 1079-1086
CrossRef380
Hyoung Moo Park. (2006) Climacteric Symptoms & Hormone Therapy. Journal of the Korean Medical Association 49:1, 11
CrossRef381
Patricia A. Carney, Anna N.A. Tosteson, Linda Titus-Ernstoff, Julia E. Weiss, Martha E. Goodrich, Paul Manganiello, Claudia J. Kasales. (2006) Hormone therapies in women aged 40 and older: Prevalence and correlates of use. Maturitas 53:1, 65-76
CrossRef382
W.J. Elliott. (2006) Folate Intake and the Risk of Incident Hypertension Among US Women. Yearbook of Cardiology 2006, 23-24
CrossRef383
Francine Grodstein, Joann E. Manson, Meir J. Stampfer. (2006) Hormone Therapy and Coronary Heart Disease: The Role of Time since Menopause and Age at Hormone Initiation. Journal of Women's Health 15:1, 35-44
CrossRef384
Adam Whaley-Connell, John Palmer, James R Sowers. (2005) Can drospirenone with 17-β estradiol safely reduce blood pressure in hypertensive postmenopausal women?. Nature Clinical Practice Endocrinology & Metabolism 1:2, 72-73
CrossRef385
James A. Swift, Peter Conway, David W. Purdie. (2005) A cost-utility analysis of low-dose hormone replacement therapy in postmenopausal women with an intact uterus. Current Medical Research and Opinion 21:12, 2051-2061
CrossRef386
Edward L. Klaiber, William Vogel, Susan Rako. (2005) A critique of the Women’s Health Initiative hormone therapy study. Fertility and Sterility 84:6, 1589-1601
CrossRef387
Miguel A. Hernán, James M. Robins, Luis A. García Rodríguez. (2005) Discussion on "Statistical Issues Arising in the Women's Health Initiative". Biometrics 61:4, 922-930
CrossRef388
Ross L. Prentice, Mary Pettinger, Garnet L. Anderson. (2005) Statistical Issues Arising in the Women's Health Initiative. Biometrics 61:4, 899-911
CrossRef389
Liqin Zhao, Kathleen O’Neill, Roberta Diaz Brinton. (2005) Selective estrogen receptor modulators (SERMs) for the brain: Current status and remaining challenges for developing NeuroSERMs. Brain Research Reviews 49:3, 472-493
CrossRef390
Veronica Ravnikar. (2005) The new hormone therapy problem: do we solve it with long-cycle progesterone therapy?. Menopause 12:6, 664-667
CrossRef391
Hsiang-Tai Chao, Cheng-Deng Kuo, Yi-Ju Su, Shin-Shin Chuang, Ya-Jing Fang, Low-Tone Ho. (2005) Short-term effect of transdermal estrogen on autonomic nervous modulation in postmenopausal women. Fertility and Sterility 84:5, 1477-1483
CrossRef392
Anne Z Steiner, Howard N Hodis, Rogerio A Lobo, Donna Shoupe, Min Xiang, Wendy J Mack. (2005) Postmenopausal oral estrogen therapy and blood pressure in normotensive and hypertensive subjects: the Estrogen in the Prevention of Atherosclerosis Trial. Menopause 12:6, 728-733
CrossRef393
Georg Kretzschmar, Thomas Nisslein, Oliver Zierau, Günter Vollmer. (2005) No estrogen-like effects of an isopropanolic extract of Rhizoma Cimicifugae racemosae on uterus and vena cava of rats after 17 day treatment. The Journal of Steroid Biochemistry and Molecular Biology 97:3, 271-277
CrossRef394
Yong Du, Hans-Ulrich Melchert, Monika Schäfer-Korting. (2005) Hormone replacement therapy in Germany: Determinants and possible health-related outcomes. Maturitas 52:3-4, 223-234
CrossRef395
Nancy Kim, Cary Gross, Jeptha Curtis, Glen Stettin, Stephen Wogen, Nami Choe, Harlan M. Krumholz. (2005) The Impact of Clinical Trials on the Use of Hormone Replacement Therapy. A Population-Based Study. Journal of General Internal Medicine 20:11, 1026-1031
CrossRef396
Sukesh Burjonroppa, Ken Fujise. 2005. Resveratrol as Cardioprotective Agent. , 539-555.
CrossRef397
Johanna M. Seddon, Clara A. Chen. (2005) The Epidemiology of Age-Related Macular Degeneration. International Ophthalmology Clinics 44:4, 17-39
CrossRef398
Sigrid Vorobjov, Sirpa-Liisa Hovi, Piret Veerus, Heti Pisarev, Mati Rahu, Elina Hemminki. (2005) Treatment adherence in the Estonian postmenopausal hormone therapy (EPHT) trial [ISRCTN35338757]. Maturitas 52:3-4, 286-295
CrossRef399
Freek WA Verheugt, Sidney C Smith. (2005) The lady aspirin for cardiovascular disease. The Lancet 366:9492, 1148-1150
CrossRef400
R. Erkkola, L. Mattila, T. Powles, J. Heikkinen, B. Toivola, P. Korhonen, M. Mustonen. (2005) Bone Mineral Density and Lipid Changes During 5 Years of Follow-up in a Study of Prevention of Breast Cancer with Toremifene in Healthy, High-risk Pre- and Post-menopausal Women. Breast Cancer Research and Treatment 93:3, 277-287
CrossRef401
Tatjana E. Vogelvang, Velja Mijatovic, Peter Kenemans, Jef J. Emeis, Johannes A. Heijst, Marius J. van der Mooren. (2005) The effects of 12 weeks of HMR 3339, a novel selective estrogen receptor modulator, on markers of coagulation and fibrinolysis: A randomized, placebo-controlled, double-blind, dose-ranging study in healthy postmenopausal women. American Journal of Obstetrics and Gynecology 193:4, 1384-1394
CrossRef402
C. Gohlke-Bärwolf, C. Schacky. (2005) Stellenwert der Hormonersatztherapie zur Prävention der koronaren Herzerkrankung bei Frauen. Zeitschrift für Kardiologie 94:S3, iii74-iii78
CrossRef403
Patrick Neven, Deborah Quail, Fernando Marin, George Creatsas, Herman Depypere, Tomasz Rechberger, Soyi Liu-Léage, Imre Pavo, Henri Schmitt, Thomas Nickelsen. (2005) Comparing raloxifene with continuous combined estrogen–progestin therapy in postmenopausal women: Review of Euralox 1. Maturitas 52:2, 87-101
CrossRef404
Claire S Duvernoy. (2005) Coronary heart disease in women: what do we know now?. Future Cardiology 1:5, 617-628
CrossRef405
Robert P. Kauffman, V. Daniel Castracane, Catherine L. Van Hook. (2005) Postmenopausal Hormone Therapy and Informed Consent: A Call for Common Sense. Journal of Women's Health 14:7, 592-594
CrossRef406
Majoie Hemelaar, Marius J van der Mooren, W Marchien van Baal, Casper G Schalkwijk, Peter Kenemans, Coen D. A Stehouwer. (2005) Effects of transdermal and oral postmenopausal hormone therapy on vascular function: a randomized, placebo-controlled study in healthy postmenopausal women. Menopause 12:5, 526-535
CrossRef407
Cynthia J Lees, Antwan G. H Ederveen, Cees P. M Spanjers, Thomas B Clarkson. (2005) Effects of tibolone on bone quality in ovariectomized monkeys. Menopause 12:5, 613-618
CrossRef408
Maria Grazia Modena, Piero Sismondi, Alfred O. Mueck, Frédérique Kuttenn, Bruno de Lignières, Johan Verhaeghe, Jean Michel Foidart, Anne Caufriez, Andrea Riccardo Genazzani. (2005) New evidence regarding hormone replacement therapies is urgently required. Maturitas 52:1, 1-10
CrossRef409
Abdulbaset Elfituri, Fathi Sherif, Mohamed Elmahaishi, Henry Chrystyn. (2005) Two hormone replacement therapy (HRT) regimens for middle-eastern postmenopausal women. Maturitas 52:1, 52-59
CrossRef410
Mikael Hoffmann, Mats Hammar, Karin I. Kjellgren, Lotta Lindh-Åstrand, Jan Brynhildsen. (2005) Changes in women's attitudes towards and use of hormone therapy after HERS and WHI. Maturitas 52:1, 11-17
CrossRef411
(2005) Discussion. American Journal of Obstetrics and Gynecology 193:2, 556-557
CrossRef412
S. Frei-Kleiner, W. Schaffner, V.W. Rahlfs, Ch. Bodmer, M. Birkhäuser. (2005) Cimicifuga racemosa dried ethanolic extract in menopausal disorders: a double-blind placebo-controlled clinical trial. Maturitas 51:4, 397-404
CrossRef413
Sirpa-Liisa Hovi, Piret Veerus, Helle Karro, Päivi Topo, Elina Hemminki. (2005) Women's views of the climacteric at the time of low menopausal hormone use, Estonia 1998. Maturitas 51:4, 413-425
CrossRef414
Cindy Farquhar, Jane Marjoribanks, Russell Basser, Sarah E Hetrick, Anne Lethaby, Cindy Farquhar. 2005. High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with metastatic breast cancer. .
CrossRef415
Cindy Farquhar, Jane Marjoribanks, Anne Lethaby, Jane A Suckling, Quirine Lamberts, Cindy Farquhar. 2005. Long term hormone therapy for perimenopausal and postmenopausal women. .
CrossRef416
Ross L. Prentice, Garnet L. Anderson. 2005. Women's Health Initiative: Statistical Aspects and Selected Early Results. .
CrossRef417
Martha Hickey, Susan R Davis, David W Sturdee. (2005) Treatment of menopausal symptoms: what shall we do now?. The Lancet 366:9483, 409-421
CrossRef418
Elizabeth J. Kovacs. (2005) Aging, traumatic injury, and estrogen treatment. Experimental Gerontology 40:7, 549-555
CrossRef419
Sharon J Rolnick, Richard A Kopher, Terese A DeFor, Mary E Kelley. (2005) Hormone use and patient concerns after the findings of the Women??s Health Initiative. Menopause 12:4, 399-404
CrossRef420
John C. Stevenson. (2005) Author's reply. The Obstetrician & Gynaecologist 7:3, 212-213
CrossRef421
David H Barlow. (2005) Does hormone replacement therapy have a future?. Women's Health 1:1, 5-8
CrossRef422
Mara A. Schonberg, Christina C. Wee. (2005) Menopausal Symptom Management and Prevention Counseling after the Women's Health Initiative among Women Seen in an Internal Medicine Practice. Journal of Women's Health 14:6, 507-514
CrossRef423
Peter Mauch, Andrea Ng, Berthe Aleman, Patrice Carde, Louis Constine, Volker Diehl, Ketayun Dinshaw, Mary Gospodarowicz, Steve Hancock, David Hodgson, Richard Hoppe, Raymond Liang, Markus Loeffler, Lena Specht, Lois B. Travis, Andrew Wirth, Joachim Yahalom. (2005) Report from the Rockefellar Foundation Sponsored International Workshop on reducing mortality and improving quality of life in long-term survivors of Hodgkin's disease: July 9-16, 2003, Bellagio, Italy. European Journal of Haematology 75, 68-76
CrossRef424
Roksana Karim, Wendy J Mack, Roger A Lobo, Juliana Hwang, Chao-ran Liu, Ci-hua Liu, Alex Sevanian, Howard N Hodis. (2005) Determinants of the effect of estrogen on the progression of subclinical atherosclerosis: Estrogen in the Prevention of Atherosclerosis Trial. Menopause 12:4, 366-373
CrossRef425
Leon Speroff. (2005) Postmenopausal hormone therapy and cardiovascular disease: one view of the elephant. Menopause 12:4, 357-358
CrossRef426
Nanette K. Wenger. (2005) Menopausal hormone therapy: Currently no evidence for cardiac protection. Pediatric Blood & Cancer 44:7, 625-629
CrossRef427
Mamta Agarwal, Vani Selvan, Barry I. Freedman, Yongmei Liu, Lynne E. Wagenknecht. (2005) The Relationship Between Albuminuria and Hormone Therapy in Postmenopausal Women. American Journal of Kidney Diseases 45:6, 1019-1025
CrossRef428
Murray Esler, Tye Dawood. (2005) Is “cardiovascular protection” by estrogens due to inhibition of the sympathetic nervous system?. Clinical Autonomic Research 15:3, 186-188
CrossRef429
J. Esteban-Altirriba. (2005) Isoflavonas y menopausia. Clínica e Investigación en Ginecología y Obstetricia 32:3, 92-98
CrossRef430
S.MITCHELL HARMAN, FREDERICK NAFTOLIN, ELIOT A. BRINTON, DEBRA R. JUDELSON. (2005) Is the Estrogen Controversy Over? Deconstructing the Women's Health Initiative Study: A Critical Evaluation of the Evidence. Annals of the New York Academy of Sciences 1052:1, 43-56
CrossRef431
Valerie Beral, Gillian Reeves, Emily Banks. (2005) Current evidence about the effect of hormone replacement therapy on the incidence of major conditions in postmenopausal women. BJOG: An International Journal of Obstetrics and Gynaecology 112:6, 692-695
CrossRef432
Laura J. Tivis, Michelle D. Richardson, Erica Peddi, Bahram Arjmandi. (2005) Saliva versus serum estradiol: Implications for research studies using postmenopausal women. Progress in Neuro-Psychopharmacology and Biological Psychiatry 29:5, 727-732
CrossRef433
Matthew J. Budoff, Race Pei-Wen Chen, Carol J. Hunter, Junichiro Takasu, Nisha Agrawal, Boris Sorochinsky, Songshou Mao. (2005) Effects of Hormone Replacement on Progression of Coronary Calcium as Measured by Electron Beam Tomography. Journal of Women's Health 14:5, 410-417
CrossRef434
Mónica Fernández, Jaime Calvo-Alén, Graciela S. Alarcón, Jeffrey M. Roseman, Holly M. Bastian, Barri J. Fessler, Gerald McGwin, Luis M. Vilá, Martha L. Sanchez, John D. Reveille, . (2005) Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXI. Disease activity, damage accrual, and vascular events in pre- and postmenopausal women. Arthritis & Rheumatism 52:6, 1655-1664
CrossRef435
Russell O. Potts, Rogerio A. Lobo. (2005) Transdermal Drug Delivery: Clinical Considerations for the Obstetrician–Gynecologist. Obstetrics & Gynecology 105:5, Part 1, 953-961
CrossRef436
Rogerio A. Lobo. (2005) Appropriate use of hormones should alleviate concerns of cardiovascular and breast cancer risk. Maturitas 51:1, 98-109
CrossRef437
David H. Barlow. (2005) Menopause and HRT – the state of the art in Europe. Maturitas 51:1, 40-47
CrossRef438
Juuso Mäkinen, Mikko J. Järvisalo, Pasi Pöllänen, Antti Perheentupa, Kerttu Irjala, Markku Koskenvuo, Juha Mäkinen, Ilpo Huhtaniemi, Olli T. Raitakari. (2005) Increased Carotid Atherosclerosis in Andropausal Middle-Aged Men. Journal of the American College of Cardiology 45:10, 1603-1608
CrossRef439
Thomas B. Clarkson, Susan E. Appt. (2005) Controversies about HRT—lessons from monkey models. Maturitas 51:1, 64-74
CrossRef440
The IMS Executive Committee. (2005) Guidelines for hormone treatment of women in the menopausal transition and beyond. Maturitas 51:1, 15-20
CrossRef441
Ruediger Osmers, Michael Friede, Eckehard Liske, Joerg Schnitker, Johannes Freudenstein, Hans-Heinrich Henneicke-von Zepelin. (2005) Efficacy and Safety of Isopropanolic Black Cohosh Extract for Climacteric Symptoms. Obstetrics & Gynecology 105:5, Part 1, 1074-1083
CrossRef442
Jacques E. Rossouw. (2005) Coronary heart disease in menopausal women: Implications of primary and secondary prevention trials of hormones. Maturitas 51:1, 51-63
CrossRef443
Nicola Colacurci, Antonio Chi??ntera, Felice Fornaro, Vito de Novellis, Daniela Manzella, Alessandro Arciello, Vito Chi??ntera, Lucio Improta, Giuseppe Paolisso. (2005) Effects of soy isoflavones on endothelial function in healthy postmenopausal women. Menopause 12:3, 299-307
CrossRef444
P. Betancor León, E. Betancor Santana. (2005) La terapia hormonal sustitutiva: mandan las evidencias. Revista Española de Enfermedades Metabólicas Óseas 14:3, 46-51
CrossRef445
Iolente J. M Korstjens, Raimond G. V Smolders, Marius J van der Mooren, Helenius J Kloosterboer, Peter Kenemans, Pieter Sipkema. (2005) Endothelium-dependent dilatory effects of 3??-OH-tibolone in gracilis muscle arterioles of the female Wistar rat. Menopause 12:3, 340-347
CrossRef446
Amos Pines. (2005) WHI and aftermath: looking beyond the figures. Maturitas 51:1, 48-50
CrossRef447
Daniel Schneider, Judith Hsia. (2005) Coronary heart disease prevention in menopausal women. Expert Opinion on Pharmacotherapy 6:5, 695-705
CrossRef448
Charles B. Hammond. (2005) The Women?s Health Initiative Study: Perspectives and Implications for Clinical Practice. Reviews in Endocrine and Metabolic Disorders 6:2, 93-99
CrossRef449
Alessandra Graziottin. (2005) The woman patient after WHI. Maturitas 51:1, 29-37
CrossRef450
Elizabeth Barrett-Connor, Deborah Grady, Marcia L. Stefanick. (2005) THE RISE AND FALL OF MENOPAUSAL HORMONE THERAPY. Annual Review of Public Health 26:1, 115-140
CrossRef451
Tommaso Simoncini, Letizia Fornari, Paolo Mannella, Gaetano Varone, Antonella Caruso, Silvia Garibaldi, Andrea R. Genazzani. (2005) Differential estrogen signaling in endothelial cells upon pulsed or continuous administration. Maturitas 50:4, 247-258
CrossRef452
J. Ness, W. S. Aronow, E. Newkirk, D. McDanel. (2005) Use of Hormone Replacement Therapy by Postmenopausal Women After Publication of the Women's Health Initiative Trial. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 60:4, 460-462
CrossRef453
Leon Speroff. (2005) Clinical appraisal of the Women's Health Initiative. Journal of Obstetrics and Gynaecology Research 31:2, 80-93
CrossRef454
Ridker, Paul M, Cook, Nancy R., Lee, I-Min, Gordon, David, Gaziano, J. Michael, Manson, JoAnn E., Hennekens, Charles H., Buring, Julie E., . (2005) A Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in Women. New England Journal of Medicine 352:13, 1293-1304
Full Text455
J. Cuzick. (2005) Radiotherapy for Breast Cancer. JNCI Journal of the National Cancer Institute 97:6, 406-407
CrossRef456
Michelle J. Naughton, Alison Snow Jones, Sally A. Shumaker. (2005) When Practices, Promises, Profits, and Policies Outpace Hard Evidence: The Post-Menopausal Hormone Debate. Journal of Social Issues 61:1, 159-179
CrossRef457
Richard R. Cline, Joel F. Farley, Richard A. Hansen, Jon C. Schommer. (2005) Osteoporosis beliefs and antiresorptive medication use. Maturitas 50:3, 196-208
CrossRef458
Diego G. Espinosa-Heidmann, Maria E. Marin-Castano, Simone Pereira-Simon, Eleut P. Hernandez, Sharon Elliot, Scott W. Cousins. (2005) Gender and estrogen supplementation increases severity of experimental choroidal neovascularization. Experimental Eye Research 80:3, 413-423
CrossRef459
Lawrence S. Phillips, Robert D. Langer. (2005) Postmenopausal hormone therapy: Critical reappraisal and a unified hypothesis. Fertility and Sterility 83:3, 558-566
CrossRef460
O. Ylikorkala, T. Mikkola. (2005) Cardiovascular consequences of hormone therapy in postmenopausal women: Messages to clinicians. Reproductive Medicine and Biology 4:1, 1-6
CrossRef461
Evelyn Perez, Ran Liu, Shao-Hua Yang, Zu Yun Cai, Douglas F. Covey, James W. Simpkins. (2005) Neuroprotective effects of an estratriene analog are estrogen receptor independent in vitro and in vivo. Brain Research 1038:2, 216-222
CrossRef462
Ryan H. Dougherty, Jacqueline L. Rohrer, Douglas Hayden, Stephen D. Rubin, Benjamin Z. Leder. (2005) Effect of aromatase inhibition on lipids and inflammatory markers of cardiovascular disease in elderly men with low testosterone levels. Clinical Endocrinology 62:2, 228-235
CrossRef463
David F. Ransohoff. (2005) Opinion: Bias as a threat to the validity of cancer molecular-marker research. Nature Reviews Cancer 5:2, 142-149
CrossRef464
Shelley Salpeter. (2005) Hormone therapy for younger postmenopausal women: how can we make sense out of the evidence?. Climacteric 8:4, 307-310
CrossRef465
ENEY O. FERNANDES, RUY S. MORAES, ELTON L. FERLIN, MARIA CELESTE O. WENDER, JORGE P. RIBEIRO. (2005) Hormone Replacement Therapy Does Not Affect the 24-Hour Heart Rate Variability in Postmenopausal Women:. Results of a Randomized, Placebo-Controlled Trial with Two Regimens. Pacing and Clinical Electrophysiology 28:s1, S172-S177
CrossRef466
Alessandra Crisafulli, Domenica Altavilla, Herbert Marini, Alessandra Bitto, Domenico Cucinotta, Nicola Frisina, Francesco Corrado, Rosario D'Anna, Giovanni Squadrito, Elena B. Adamo, Rolando Marini, Adolfo Romeo, Francesco Cancellieri, Michele Buemi, Francesco Squadrito. (2005) Effects of the phytoestrogen genistein on cardiovascular risk factors in postmenopausal women. Menopause 12:2, 186-192
CrossRef467
Ki Ok Han. (2005) Hormone Therapy in Postmenopausal Women. Journal of the Korean Medical Association 48:4, 377
CrossRef468
William T. Creasman. (2005) Reply. American Journal of Obstetrics and Gynecology 192:1, 334
CrossRef469
Tommaso Simoncini, Letizia Fornari, Paolo Mannella, Antonella Caruso, Silvia Garibaldi, Chiara Baldacci, Andrea R. Genazzani. (2005) Activation of nitric oxide synthesis in human endothelial cells by red clover extracts. Menopause 12:1, 69-77
CrossRef470
M.D. Kesim, Y. Aydin, M. Erdemir, A. Atis. (2005) Nitric oxide in postmenopausal women taking three different HRT regimens. Maturitas 50:1, 52-57
CrossRef471
Leslie Cho, Debabrata Mukherjee. (2005) Hormone Replacement Therapy and Secondary Cardiovascular Prevention: A Meta-Analysis of Randomized Trials. Cardiology 104:3, 143-147
CrossRef472
David Hamerman. (2005) Bone health across the generations: a primer for health providers concerned with osteoporosis prevention. Maturitas 50:1, 1-7
CrossRef473
Beth A. Mohr, Andre T. Guay, Amy B. O'Donnell, John B. McKinlay. (2005) Normal, bound and nonbound testosterone levels in normally ageing men: results from the Massachusetts Male Ageing Study. Clinical Endocrinology 62:1, 64-73
CrossRef474
Cheryl A. Keech, Andreas Sashegyi, Elizabeth Barrett-Connor. (2005) Year-by-year analysis of cardiovascular events in the Multiple Outcomes of Raloxifene Evaluation (MORE) trial*. Current Medical Research and Opinion 21:1, 135-140
CrossRef475
Judith F. Barnes, Elizabeth Farish, Marion Rankin, David M. Hart. (2005) Effects of two continuous hormone therapy regimens on C-reactive protein and homocysteine. Menopause 12:1, 92-98
CrossRef476
Susan E Bromley, Corinne S de Vries, Dawn Thomas, Richard D T Farmer. (2005) Hormone Replacement Therapy and Risk of Acute Myocardial Infarction. Drug Safety 28:6, 473-493
CrossRef477
Michele L. Evans, Elizabeth Pritts, Eric Vittinghoff, Karen McClish, Kevin S. Morgan, Robert B. Jaffe. (2005) Management of Postmenopausal Hot Flushes With Venlafaxine Hydrochloride: A Randomized, Controlled Trial. Obstetrics & Gynecology 105:1, 161-166
CrossRef478
Stephen L Archer, Ferrante S Gragasin, Linda Webster, Derek Bochinski, Evangelos D Michelakis. (2005) Aetiology and Management of Male Erectile Dysfunction and Female Sexual Dysfunction in Patients with Cardiovascular Disease. Drugs & Aging 22:10, 823-844
CrossRef479
Renaud Piarroux, Fr??d??ric Grenouillet, Patrick Balvay, V??ronique Tran, Gilles Blasco, Laurence Millon, Annie Boillot. (2004) Assessment of preemptive treatment to prevent severe candidiasis in critically ill surgical patients(*). Critical Care Medicine 32:12, 2443-2449
CrossRef480
Rogerio A. Lobo. (2004) Areas for future inquiry. Endocrinology & Metabolism Clinics of North America 33:4, 761-769
CrossRef481
Faustino R. Pérez-López. (2004) An evaluation of the contents and quality of menopause information on the World Wide Web. Maturitas 49:4, 276-282
CrossRef482
Fahad S. Hanna, Anita E. Wluka, Robin J. Bell, Susan R. Davis, Flavia M. Cicuttini. (2004) Osteoarthritis and the postmenopausal woman: Epidemiological, magnetic resonance imaging, and radiological findings. Seminars in Arthritis and Rheumatism 34:3, 631-636
CrossRef483
Susan D. Reed, Katherine M. Newton, Andrea Z. LaCroix. (2004) Indications for hormone therapy: the post-Women's Health Initiative era. Endocrinology & Metabolism Clinics of North America 33:4, 691-715
CrossRef484
Tatjana E. Vogelvang, Velja Mijatovic, Peter Kenemans, Tom Teerlink, Marius J. van der Mooren. (2004) HMR 3339, a novel selective estrogen receptor modulator, reduces total cholesterol, low-density lipoprotein cholesterol, and homocysteine in healthy postmenopausal women. Fertility and Sterility 82:6, 1540-1549
CrossRef485
Ross L. Prentice. (2004) Chronic disease prevention: public health potential and research needs. Statistics in Medicine 23:22, 3409-3420
CrossRef486
G. D. O. Lowe. (2004) Hormone replacement therapy and cardiovascular disease: increased risks of venous thromboembolism and stroke, and no protection from coronary heart disease. Journal of Internal Medicine 256:5, 361-374
CrossRef487
E. Windler. (2004) Kardiovaskul
CrossRef488
Naftali Raz, Karen M. Rodrigue, Kristen M. Kennedy, James D. Acker. (2004) Hormone replacement therapy and age-related brain shrinkage: regional effects. NeuroReport 15:16, 2531-2534
CrossRef489
C.A. Barber, K. Margolis, R.V. Luepker, D.K. Arnett. (2004) The Impact of the Women's Health Initiative on Discontinuation of Postmenopausal Hormone Therapy: The Minnesota Heart Survey (2000–2002). Journal of Women's Health 13:9, 975-985
CrossRef490
C. Azoulay. (2004) Ménopause en 2004 : le « traitement hormonal substitutif » n'est plus ce qu'il était. La Revue de Médecine Interne 25:11, 806-815
CrossRef491
Brendon Yee, Peter Liu, Craig Phillips, Ron Grunstein. (2004) Neuroendocrine changes in sleep apnea. Current Opinion in Pulmonary Medicine 10:6, 475-481
CrossRef492
S. Graff-Iversen, N. Hammar, D. S. Thelle, S. Tonstad. (2004) Hormone therapy and mortality during a 14-year follow-up of 14 324 Norwegian women. Journal of Internal Medicine 256:5, 437-445
CrossRef493
&NA;. (2004) Coronary Heart Disease. Obstetrics & Gynecology 104:Supplement, 41S-48S
CrossRef494
(2004) Estrogen and progestogen therapy in postmenopausal women. Fertility and Sterility 82, 70-80
CrossRef495
Kjersti Bakken, Anne Elise Eggen, Eiliv Lund. (2004) Side-effects of hormone replacement therapy and influence on pattern of use among women aged 45-64 years. The Norwegian Women and Cancer (NOWAC) study 1997. Acta Obstetricia et Gynecologica Scandinavica 83:9, 850-856
CrossRef496
T.Matthew Shields, Charles H Hennekens. (2004) Management of metabolic syndrome: aspirin. Endocrinology & Metabolism Clinics of North America 33:3, 577-593
CrossRef497
Renee M. Brennan, Carlos J. Crespo, Jean Wactawski-Wende. (2004) Health behaviors and other characteristics of women on hormone therapy: results from the Third National Health and Nutrition Examination Survey, 1988???1994. Menopause 11:5, 536-542
CrossRef498
Lars H. Lund, Donna Mancini. (2004) Heart failure in women. Medical Clinics of North America 88:5, 1321-1345
CrossRef499
L Vehmanen, T Saarto, C Blomqvist, M-R Taskinen, I Elomaa. (2004) Tamoxifen treatment reverses the adverse effects of chemotherapy-induced ovarian failure on serum lipids. British Journal of Cancer 91:3, 476-481
CrossRef500
Wendy J Mack, Cristin C Slater, Min Xiang, Donna Shoupe, Rogerio A Lobo, Howard N Hodis. (2004) Elevated subclinical atherosclerosis associated with oophorectomy is related to time since menopause rather than type of menopause. Fertility and Sterility 82:2, 391-397
CrossRef501
David B. Reuben. (2004) Confronting the Geriatrician's Nightmare. Journal of the American Geriatrics Society 52:8, 1393-1394
CrossRef502
Mary Seed, Robert H Knopp. (2004) Estrogens, lipoproteins, and cardiovascular risk factors: an update following the randomized placebo-controlled trials of hormone-replacement therapy. Current Opinion in Lipidology 15:4, 459-467
CrossRef503
Til Stürmer, JoAnn E. Manson. (2004) Estrogens and breast cancer: does timing really matter?. Journal of Clinical Epidemiology 57:8, 763-765
CrossRef504
Elizabeth Barrett-Connor, Jane A Cauley, Pandurang M Kulkarni, Andreas Sashegyi, David A Cox, Mary Jane Geiger. (2004) Risk-Benefit Profile for Raloxifene: 4-Year Data From the Multiple Outcomes of Raloxifene Evaluation (MORE) Randomized Trial. Journal of Bone and Mineral Research 19:8, 1270-1275
CrossRef505
David A. Cox, Somnath Sarkar, Kristine Harper, Elizabeth Barrett-Connor. (2004) Effect of raloxifene on the incidence of elevated low density lipoprotein (LDL) and achievement of LDL target goals in postmenopausal women. Current Medical Research and Opinion 20:7, 1049-1055
CrossRef506
János Nemcsik, Éva Morschl, József Egresits, Krisztina Kordás, Ferenc László, Ferenc A László, Imre Pávó. (2004) Raloxifene lowers ischaemia susceptibility by increasing nitric oxide generation in the heart of ovariectomized rats in vivo. European Journal of Pharmacology 495:2-3, 179-184
CrossRef507
Michael Clearfield. (2004) Coronary Heart Disease Risk Reduction in Postmenopausal Women: The Role of Statin Therapy and Hormone Replacement Therapy. Preventive Cardiology 7:3, 131-136
CrossRef508
Mario Di Napoli, Francesca Papa. (2004) Clinical application of C-reactive protein in stroke prevention: bright and dark sides of the moon. Expert Review of Neurotherapeutics 4:4, 613-622
CrossRef509
Marjorie Luckey, Risa Kagan, Susan Greenspan, Henry Bone, R. Douglas P. Kiel, James Simon, Jennifer Sackarowitz, Joanne Palmisano, Erluo Chen, Richard A. Petruschke, Anne E. de Papp. (2004) Once-weekly alendronate 70 mg and raloxifene 60 mg daily in the treatment of postmenopausal osteoporosis*. Menopause 11:4, 405-415
CrossRef510
Shelley R. Salpeter, Judith M.E. Walsh, Elizabeth Greyber, Thomas M. Ormiston, Edwin E. Salpeter. (2004) Mortality Associated with Hormone Replacement Therapy in Younger and Older Women. A Meta-analysis. Journal of General Internal Medicine 19:7, 791-804
CrossRef511
Marilyn M. Schapira, Joan Neuner. (2004) The Continuing Evolution of Women's Health. Journal of General Internal Medicine 19:7, 810-811
CrossRef512
Diane S. Aschenbrenner. (2004) HRT Reconsidered. AJN, American Journal of Nursing 104:6, 51-53
CrossRef513
Michael Von Korff, Richard A. Deyo. (2004) Potent opioids for chronic musculoskeletal pain: flying blind?. Pain 109:3, 207-209
CrossRef514
Frederick Naftolin, Hugh S. Taylor, Richard Karas, Eliot Brinton, Isadore Newman, Thomas B. Clarkson, Michael Mendelsohn, Rogerio A. Lobo, Debra R. Judelson, Lila E. Nachtigall, Christopher B. Heward, Harvey Hecht, Michael R. Jaff, S.Mitchell Harman. (2004) The Women's Health Initiative could not have detected cardioprotective effects of starting hormone therapy during the menopausal transition. Fertility and Sterility 81:6, 1498-1501
CrossRef515
ROGERIO A. LOBO. (2004) Views on Recent Trials and the Future of Hormonal Therapy. Clinical Obstetrics and Gynecology 47:2, 424-427
CrossRef516
RICHARD H. KARAS. (2004) Current Controversies Regarding the Cardiovascular Effects of Hormone Therapy. Clinical Obstetrics and Gynecology 47:2, 489-499
CrossRef517
(2004) Vitamin E taken as capsules does not affect cataract incidence and progression. Focus on Alternative and Complementary Therapies 9:2, 130-131
CrossRef518
G A Figtree, B G Robinson. (2004) Estrogen receptor polymorphisms in common disease: recent developments. Current Opinion in Endocrinology & Diabetes 11:3, 141-146
CrossRef519
Heather G. Miller, Rose Maria Li. (2004) Measuring Hot Flashes: Summary of a National Institutes of Health Workshop. Mayo Clinic Proceedings 79:6, 777-781
CrossRef520
H. G. Miller, R. M. Li. (2004) Measuring Hot Flashes: Summary of a National Institutes of Health Workshop. Mayo Clinic Proceedings 79:6, 777-781
CrossRef521
Farook Al-Azzawi. (2004) The turbulent seas of women’s health—who is the beneficiary?. Maturitas 48:1, 5-7
CrossRef522
I. F. Godsland, N. A. Manassiev, C. V. Felton, A. J. Proudler, D. Crook, M. I. Whitehead, J. C. Stevenson. (2004) Effects of low and high dose oestradiol and dydrogesterone therapy on insulin and lipoprotein metabolism in healthy postmenopausal women. Clinical Endocrinology 60:5, 541-549
CrossRef523
A. A. Ajayi, G. O. Ogungbade, A. O. Okorodudu. (2004) Sex hormone regulation of systemic endothelial and renal microvascular reactivity in type-2 diabetes: studies in gonadectomized and sham-operated Zucker diabetic rats. European Journal of Clinical Investigation 34:5, 349-357
CrossRef524
Jean Wright. (2004) Guidelines for the hormone treatment of women in the menopausal transition and beyond. Maturitas 48:1, 27-31
CrossRef525
Leon Speroff. (2004) WHI estrogen-only arm is canceled. Maturitas 48:1, 3-4
CrossRef526
Aafje Sierksma, Taisto Sarkola, C. J. Peter Eriksson, Martijn S. Gaag, Diederick E. Grobbee, Henk F. J. Hendriks. (2004) Effect of Moderate Alcohol Consumption on Plasma Dehydroepiandrosterone Sulfate, Testosterone, and Estradiol Levels in Middle-Aged Men and Postmenopausal Women: A Diet-Controlled Intervention Study. Alcoholism: Clinical and Experimental Research 28:5, 780-785
CrossRef527
J. E. Morley. (2004) Is the Hormonal Fountain of Youth Drying Up?. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 59:5, M458-M460
CrossRef528
Angela H.E.M. Maas, Yolanda van der Graaf, Yvonne T. van der Schouw, Diederick E. Grobbee. (2004) HRT and heart disease: problems and prospects. Maturitas 47:4, 255-258
CrossRef529
John A. Goldman. (2004) Women??s Health Initiative Perspective. JCR: Journal of Clinical Rheumatology 10:2, 97-99
CrossRef530
Lori Mosca, Lawrence J Appel, Emelia J Benjamin, Kathy Berra, Nisha Chandra-Strobos, Rosalind P Fabunmi, Deborah Grady, Constance K Haan, Sharonne N Hayes, Debra R Judelson, Nora L Keenan, Patrick McBride, Suzanne Oparil, Pamela Ouyang, Mehmet C Oz, Michael E Mendelsohn, Richard C Pasternak, Vivian W Pinn, Rose Marie Robertson, Karin Schenck-Gustafsson, Cathy A Sila, Sidney C Smith, George Sopko, Anne L Taylor, Brian W Walsh, Nanette K Wenger, Christine L Williams. (2004) Evidence-based guidelines for cardiovascular disease prevention in women. Journal of the American College of Cardiology 43:5, 900-921
CrossRef531
John C. Stevenson. (2004) Hormone replacement therapy: Review, update, and remaining questions after the women’s health initiative study. Current Osteoporosis Reports 2:1, 12-16
CrossRef532
Stefan Störk, Yvonne T. van der Schouw, Diederick E. Grobbee, Michiel L. Bots. (2004) Estrogen, inflammation and cardiovascular risk in women: a critical appraisal. Trends in Endocrinology & Metabolism 15:2, 66-72
CrossRef533
William Foster, Gregory Y. H. Lip. (2004) Hormone replacement therapy and cardiovascular disease: does route of administration and formulation matter?. British Journal of Haematology 124:6, 836-840
CrossRef534
Tabassome Simon, Pierre Boutouyrie, Anne Gompel, Sophie Christin-Maitre, Stephane Laurent, Christian Thuillez, Faiez Zannad, Corine Bernaud, Patrice Jaillon, . (2004) Rationale, design and methods of the CASHMERE study+. Fundamental and Clinical Pharmacology 18:1, 131-138
CrossRef535
Victor W Henderson. (2004) Hormone therapy and Alzheimer’s disease: benefit or harm?. Expert Opinion on Pharmacotherapy 5:2, 389-406
CrossRef536
Rhoden, Ernani Luis, Morgentaler, Abraham, . (2004) Risks of Testosterone-Replacement Therapy and Recommendations for Monitoring. New England Journal of Medicine 350:5, 482-492
Full Text537
Nanette K. Wenger. (2004) Menopausal hormone therapy: Is there evidence for cardiac protection?. International Urology and Nephrology 36:4, 617-623
CrossRef538
David H. Barlow. (2004) Psychological Treatments.. American Psychologist 59:9, 869-878
CrossRef539
Ruth Warren, Michelle Harvie, Anthony Howell. (2004) Strategies for Managing Breast Cancer Risk After the Menopause. Treatments in Endocrinology 3:5, 289-307
CrossRef540
Jason T. Call, Efthymios N. Deliargyris, L Kristin Newby. (2004) Focusing on Inflammation in the Treatment of Atherosclerosis. Cardiology in Review 12:4, 194-200
CrossRef541
Shung Chull Chae. (2004) Risk Factors and Primary and Secondary Prevention of Coronary Heart Disease. Journal of the Korean Medical Association 47:8, 704
CrossRef542
W. L. Hall, K. Vafeiadou, A. M. Minihane, C. M. Williams, G. H. Rimbach. 2004. Isoflavones and coronary heart disease. , 187-214.
CrossRef543
J. E. Morley. (2004) The Top 10 Hot Topics in Aging. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 59:1, M24-M33
CrossRef544
Nikolaus J Buchner, Lars C Rump. (2003) Oral contraceptives and endothelial function. Journal of Hypertension 21:12, 2227-2230
CrossRef545
Francine K Welty. (2003) Alternative hormone replacement regimens: is there a need for further clinical trials?. Current Opinion in Lipidology 14:6, 585-591
CrossRef546
Eric Yarnell, Kathy Abascal. (2003) Herbal Medicine for Treating Menopausal Symptoms. Alternative and Complementary Therapies 9:6, 299-306
CrossRef547
Monica P. Ramirez, Susan Haas. (2003) Hormone replacement therapy for women: the benefits, risks, and considerations for use in 2003. Current Opinion in Endocrinology & Diabetes 10:6, 400-418
CrossRef548
Tomaz Kocjan, Gordana M Prelevic. (2003) Hormone replacement therapy update: who should we be prescribing this to now?. Current Opinion in Obstetrics and Gynecology 15:6, 459-464
CrossRef549
Susan V. Bukata, John H. Healey. (2003) Osteoporosis treatment: the winds of change. Current Opinion in Orthopaedics 14:6, 438-439
CrossRef550
D. Sudhaker Rao, Sunil D. Rao. (2003) Treatment of primary hyperparathyroidism. Current Opinion in Endocrinology & Diabetes 10:6, 394-399
CrossRef551
(2003) Hormone Therapy and Cardiovascular Disease. New England Journal of Medicine 349:21, 2075-2076
Full Text552
Robert H. Knopp, Keiko Aikawa, Eleanor A. Knopp. (2003) Estrogen therapies, lipids, and the heart disease prevention controversy. Current Cardiology Reports 5:6, 477-482
CrossRef553
Leon Speroff. (2003) HT. Fertility and Sterility 80, 15-18
CrossRef554
Ken Shaw, Mike Cummings. (2003) HRT: increased cardiac risk in diabetes. Practical Diabetes International 20:8, 268-269
CrossRef555
Jun R Chiong, Alan B Miller. (2003) Agents that stabilise atherosclerotic plaque. Expert Opinion on Investigational Drugs 12:10, 1681-1692
CrossRef556
Sandra Lookinland, Renea L. Beckstrand. (2003) HRT: Decide Based on the Evidence. The Nurse Practitioner 28:9, 46-54
CrossRef557
Bailar, John, . (2003) Hormone-Replacement Therapy and Cardiovascular Diseases. New England Journal of Medicine 349:6, 521-522
Full Text558
Herrington, David M., Howard, Timothy D., . (2003) From Presumed Benefit to Potential Harm — Hormone Therapy and Heart Disease. New England Journal of Medicine 349:6, 519-521
Full Text
- Letters
